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ABSTRACT 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, clinically 
manifested by memory impairment, loss of ability in conducting daily activity and 
increased need for care, thus causing immense suffering for the afflicted and relatives, as 
well as a huge economic burden to the society. Despite the existence of symptom-relieving 
drugs, there is no drug that can stop the progression or cure the disease. Therefore, new 
disease-modifying drugs are called for. Epidemiological studies suggest that among persons 
with long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) there is a lower 
prevalence of AD, and there is extensive evidence for the presence of a chronic 
inflammation in AD, that may promote pathology and pathogenesis, presenting 
inflammation as a therapeutic target. Resolution of inflammation belongs to the last phase 
of the inflammatory response, where inflammation is down-regulated and return to 
homeostasis is promoted. Chronic inflammation can thus be a result of a failure in 
resolution mechanisms. The levels of specialized pro-resolving lipid mediators (SPMs), 
mediators of resolution derived from polyunsaturated fatty acids (PUFA), are decreased in 
chronic inflammatory diseases including AD, opening a new field of therapeutic 
intervention for AD by stimulating resolution of inflammation.  
 
In Paper I, studies on a human microglial cell line showed that both the omega-3 (n-3) FAs 
docosahexaenoic (DHA) and eicosapentaenoic acid (EPA), increased microglial 
phagocytosis of β-amyloid 1-42 (Aβ42) peptide, and down-regulated the pro-inflammatory 
phenotype. In Paper II, we asked the question how Aβ42 affects the resolution of 
inflammation. We showed that Aβ42 is more suppressive on the resolution pathway in the 
human microglia compared to the inflammation induced by lipopolysaccharide (LPS), 
indicating that there is an impairment of resolution specific for this major molecular 
pathological hallmark of AD. Paper III describes lower levels of the SPMs maresin 1 
(MaR1), protectin D1 (PD1) and resolvin (Rv) D5 in the entorhinal cortex in AD. Also, 
lipoxin A4 (LXA4), MaR1, RvD1 and protectin DX (PDX) exerted neuroprotective activity 
against staurosporine-induced apoptosis. MaR1 and RvD1 down-regulated Aβ42-induced 
pro-inflammatory activation in human microglia. Microglial phagocytosis of Aβ42 was 
increased by MaR1. Findings in Paper IV on the influence of apolipoprotein (Apo) E4 
allele on the plasma SPM levels upon n-3 FA supplementation in AD patients, indicate that 
conversion of FAs to SPMs is not increased by supplementation with n-3 FAs, and showed 
that the proportion of patients with unchanged/improved cognition was higher in the n-3 FA-
treated group compare to placebo, but only in ApoE4 non-carriers. 
 
In conclusion, these studies show that resolution of inflammation is impaired in AD, and 
support the idea that stimulating the resolution of inflammation is a potential therapeutic 
strategy in AD. 
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1 INTRODUCTION  
1.1 ALZHEIMER’S DISEASE 
In 1906, at the meeting of Psychiatrists of Southwest Germany, psychiatrist and 
neuropathologist Alois Alzheimer reported the neuropathological and clinical features of one 
of his cases, who died of dementia at the age of 55 [1]. The disease was named “Alzheimer’s 
disease” in 1910 by his senior colleague Kraepelin [2]. Actually, the clinical features of 
Alzheimer’s disease (AD) had been documented by the ancient Greeks, and Alois Alzheimer 
was not the first one to describe senile plaques, however, it was him who first reported the 
tangle pathology [2]. For a long period of time after the baptism of the disease, the term 
“Alzheimer’s disease” was only used for describing the presenile dementia (less than 65 years 
old), and scientists did not at first separate between Alzheimer’s disease and other types of 
dementia such as Pick’s disease, Creuzfeldt-Jakob disease. Not until the 1970s, it became 
clear the late-onset “senile dementia” also have AD pathology, leading to altered definitions 
together with increased research funding and attention.  
 
1.1.1 Epidemiology  
The prevalence of dementia was estimated to be 35.6 million worldwide. The number was 
expected to be double every 20 years [3]. The total estimated costs of dementia were 604 
billion dollars worldwide [4]. AD is the most common cause of dementia, accounting for 60-
80% of all dementia cases. It is estimated that one in nine people above the age of 65 has AD, 
and about one-third of those above 85 [5]. It is noteworthy that about half of these cases 
display pathological changes related to other causes of dementia such as vascular pathology 
and Lewy body pathology, indicating the complexity and heterogeneity of the disease [6]. It 
has been suggested that AD is an under-diagnosed disease, since only those with onset of the 
clinical syndrome receives the diagnosis. However, AD pathology begins considerably earlier 
than the clinical manifestations. Therefore, a lot of people have a pre-clinical stage of AD 
unknowingly. 
 
1.1.2 Risk factors 
AD is a multifactorial disease, involving both genetic and environmental factors, among 
which aging is the strongest risk factor. However, AD is not a part of normal aging. Even 
though it was first described 100 years ago, the etiology is still unclear, and a tremendous 
amount of effort will be required before we fully understand the disease. Mutations in the 
genes encoding APP, presenilin 1 and presenilin 2, give rise to familial forms of AD, 
accounting for about 5% of AD cases [7]. However, the majority of AD cases belong to the 
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sporadic form, with unclear causality. The E4 allele of the apolipoprotein E (ApoE) gene is 
the highest risk factor for sporadic AD; individuals with a single ApoE4 allele have 2-5 fold 
increased risk of developing AD, while ApoE4 double carriers have 12-17 fold increased risk 
[8]. There are 3 ApoE gene types, E2, E3 and E4, which differ by single amino acid 
interchanges at residues 112 and 158. Other risk factors for sporadic AD include family 
history [9], and risk factors that are common with cardiovascular disease such as smoking, 
obesity, diabetes, high cholesterol and hypertension at mid-age [10-12]. Social and cognitive 
inactivity, low education and traumatic brain injury are also risk factors [13]. It appears that 
rather than having a single cause, AD is probably a consequence of multiple factors 
converging on a disruption of the homeostasis in the brain. 
  
1.1.3 Clinical aspects – clinical manifestations, diagnosis and treatment 
strategy to date  
The clinical symptoms are the reflection of the pathological changes in the brain. Neurons 
and synapses represent the fundamental basis for memories, thoughts and movements. 
Defects in the function of neuronal networks and synapses followed by the death of neurons 
(i.e. neurodegeneration) are the ultimate causes for the clinical symptoms of AD. 
1.1.3.1 Clinical manifestation  
The clinical symptoms of AD vary between individuals, the most common clinical 
manifestation being a gradually worsening in remembering new information. As the disease 
progresses, other areas of the brain are affected by the neurodegeneration and cause 
additional cognitive and behavioral symptoms, clinically manifested by a general difficulty in 
thinking, reasoning, planning, and the withdrawal from social activities, changes in mood and 
personality, and also associated with depression. Eventually, basic physiological functions 
such as swallowing are impaired. The life span after the diagnosis of AD is usually less than 
10 years [14, 15]. 
1.1.3.2 Diagnosis  
The ultimate criterion for diagnosing AD is the establishment of the presence of 
histopathological hallmarks by autopsy of the post-mortem brain. However, autopsy and 
post-mortem diagnosis is more helpful for research purpose. The most commonly used 
criteria for diagnosing AD in the clinic are the International Classification of Disease, 10th 
revision (ICD-10)(WHO 1992), the Diagnostic and Statistical Manual, 4th edit, (DSM-IV) 
(American Psychiatric Association 1994), the National Institute of Neurological and 
Communicative Disorders and Stroke (NINCDS), and the Alzheimer’s Disease and Related 
Disorders Association (ADRDA) workgroup in 1984 (NINCDS-ADRDA) criteria [16]. 
However, all of these criteria have limitations, since they require memory loss and 
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impairment of at least one non-memory domain function such as language, motor, perception 
and executive function. Early diagnosis is crucial for an early intervention, and with the 
development of positron emission tomography (PET), and magnetic resonance imaging 
(MRI) technologies, together with the development of assays for the analysis of biomarkers 
of AD in biological samples, new proposals have been published for diagnosing AD. In these, 
analysis of different aspects of brain imaging, and the levels of CSF biomarkers such as Aβ42 
and tau, were incorporated [17, 18].  
1.1.3.3 Therapeutics and prevention  
Drugs that are used clinically for treatment of AD patients target the cholinergic (Donepezil, 
Galantamine, Rivastigmine, Tacrine) or glutamate (Memantine) system. However, these 
drugs only provide limited short-term relief of symptoms, without affecting the underlying 
pathological mechanisms. There is currently no drug or treatment that can halt or reverse the 
progression of the disease.  
Ongoing clinical trials include strategies that target Aβ, tau, neurotransmitters, inflammation, 
and other factors affected in AD. Several previous strategies have failed when tried in a larger 
scale [19-21], despite promising results in smaller clinical trials, shedding light on problems 
with the design of early clinical trials where patients may be “over-selected” so that they do 
not represent a general population. The lack of results after so much effort can produce a 
feeling of hopelessness. However, there are a plethora of pre-clinical studies, aiming to 
discover new treatment strategies with the ability to modify the pathological course of AD by 
affecting different pathways related to the disease. Since AD is a multifactorial disease, a 
combination of therapies, or drugs that have multiple targets, may have a higher chance for 
successful treatment. As AD pathology develops decades before the onset of clinical 
symptoms, prevention is also of great importance. Studies indicate that people with an active 
lifestyle, including physical and leisure activities, and an absence of vascular risk factors have 
a lower incidence of AD [13, 22].  
 
1.1.4 Pathological aspects  
The gross histopathology of AD is characterized by brain atrophy, deepening of the cerebral 
grooves and the enlargement of the cerebral ventricles. Histologically, AD is characterized by 
extracellular deposition of senile plaques, intracellular accumulation of neurofibrillary tangles 
(NFTs) [1], and chronic inflammation [23-26]. Genetic studies have shown that mutations in 
the amyloid β (Aβ) precursor protein (APP), or in the genes for APP-processing proteins, can 
cause early onset (familial) AD [27-29], while genes related to innate immunity and 
inflammation were found to be associated with late-onset (sporadic) AD [30, 31]. However, 
there is, so far, no evidence for mutations in the tau gene associated with AD. Even though in 
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vitro studies show that Aβ can induce tau hyperphosphorylation in neurons [32, 33], APP 
transgenic mice, which have an overabundance of Aβ, do not have tau pathology [34]. 
Interactions between the pathologies of Aβ and tau have not been clarified so far. There is 
evidence that inflammation can increase the production of Aβ and induce tau 
hyperphosphorylation in in vitro studies [35, 36]. It is highly likely that these three main 
pathological pathways interact with each other and drives the pathogenesis of AD.  
1.1.4.1 Aβ 
Aβ is a 37-43 amino acid long peptide, produced from sequential cleavage APP by the β- and 
γ-secretases [37]. Aβ has been considered as a main culprit of AD, and the Aβ hypothesis has 
been dominant for explaining the pathogenesis of AD [38]. There is a plethora of evidence 
that support the Aβ hypothesis: patients with an extra copy of chromosome 21, where the 
APP gene locates, develop dementia at an early age; APP transgenic mice exhibit significant 
cognitive impairment; the toxicity of Aβ has been documented extensively in in vitro studies 
[35, 39, 40].  
Aβ is mainly produced by neurons, and in pathological conditions misfolded and abnormally 
aggregated. The 40 amino acid long Aβ species is abundant in the AD brain, but the majority 
of studies have indicated the Aβ42 form as the main pathological species [41]. Aβ peptide is 
prone to aggregate to oligomers and large fibrils [42]. Histologically, different types of 
amyloid plaques are found in the AD brain, such as dense core and diffuse (cotton wool) 
plaques, indicating a differential aggregation status of Aβ [43]. Despite strong evidence 
supporting an etiological role of Aβ, there is no clear evidence for a correlation between the 
total Aβ burden and cognitive impairment [44]. Therefore, different aggregation forms of Aβ, 
the relative levels of which may differ between patients, may have different properties 
regarding neurotoxicity. Results from studies designed to address the neurotoxicity of 
different species of Aβ aggregation suggest that the oligomeric forms of Aβ are the most 
neurotoxic species [45, 46].  
Aβ is produced in the normal healthy brain, and under physiological conditions, Aβ can be 
degraded or cleared from the brain by different pathways. Thus, Aβ can be degraded by 
enzymes such as neprilysin, insulin-degrading enzyme (IDE), and matrix metalloproteinase 9 
(MMP9) [47-50]. Alternatively, Aβ can be transported from the brain and into the blood by 
transporters such as low-density lipoprotein-related protein (LRP) and the ATP-binding 
cassette (ABC) transporter permeability glycoprotein (P-GP) [51, 52]. In addition, Aβ can be 
cleared from the brain by non-specific flow of interstitial fluid to the blood [53]. Aβ can be 
transported into the CNS via the receptor for advanced glycation end products (RAGE) [54]. 
Therefore, a balance of the influx and efflux of Aβ to and from the brain is required to 
maintain homeostatic physiological conditions.  
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To cure a disease, the ideal way is to affect the disease etiology and target the molecule that is 
believed to drive the pathogenesis of the disease. In this regard, Aβ has received most of the 
attention during the past decade. Many hypotheses that involve Aβ production or clearance 
have been tested, both in animal models and in clinical trials, including immunization and 
inhibition of Aβ production. Great achievements have been made from the animal models. 
However, unfortunately, these findings could not be translated to humans in clinical trials due 
to insignificant beneficial effects or significant side effects (reviewed in [55]).  
1.1.4.2 Tau  
Tau is a microtubule-associated protein that binds to and stabilizes the microtubule, and 
thereby involved in the transport between the cell soma and the axonal terminals [56]. In the 
AD brain, tau protein is abnormally hyperphosphorylated, dissociated from the microtubules 
and accumulated in the soma and dendrites, there forming paired helical filaments (PHFs) 
and NFTs. The dissociation of tau from the microtubules can cause deficiency in axonal 
transport, resulting in the degeneration of the axon and causing death of the neuron [57]. In 
contrast to Aβ load, the NFT load correlates well with cognitive impairment [43]. In addition 
to a therapy based on reduction of Aβ, reducing the hyperphosphorylation of tau represents 
another major therapeutic target for AD. Strategies targeting tau pathology include 
vaccination, anti-tau aggregation [58], and the targeting of kinases that are involved in tau 
phosphorylation [59].  
  
1.2 INFLAMMATION 
The term “inflammation” was originally defined by Celsus, who described the four classical 
cardinal signs of inflammation; “tumor, rubor, calor and dolor” [60, 61]. As we grow to 
understand more about the molecular mechanisms in inflammation biology, inflammation has 
extended its original definition to a broad spectrum of situations, including diseases in the 
absence of the four cardinal signs.  
  
1.2.1 Components of inflammation  
Cellular and molecular mediators are fundamental units that mediate inflammation. Their 
levels can vary between different tissues, diseases, and even different stages of a disease. My 
thesis mainly focuses on inflammation in the brain in relation to AD except for paper IV in 
which inflammatory factors in the peripheral blood is studied. 
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1.2.1.1 Cellular components of inflammation in the brain 
The inflammatory response is a synthesis of activities, and the interactions between the cell 
types present in the brain, primarily microglia, astrocytes and neurons, although 
oligodendrocytes and brain endothelial cells also play a role [62, 63]. 
1.2.1.1.1 Microglia 
Microglial cells enter the brain during development from the yolk sac during hematopoiesis 
[64, 65], and remain in the brain as resident immune cells. Macrophages of peripheral origin 
can be found in the meninges, choroid plexus, and perivascular space. However, they cannot 
cross the blood brain barrier (BBB) under normal conditions. Therefore, the renewal of 
microglial cells in the adult brain depends on local progenitor cells [66, 67]. “Ramified” and 
“amoeboid” microglia can be found in the brain at different stages of diseases [68]. The 
morphology of microglia is adapted to their function. At the resting state, microglia exhibit a 
“ramified” morphology with long processes, thus increasing their ability to detect changes 
and threats in the microenvironment. For this function, microglial cells express various 
pattern recognition receptors (PRR) that can recognize pathogen-associated molecular 
patterns (PAMPs), and damage-associated molecular patterns (DAMPs), so that they can 
detect and respond to the threat at the place of encounter.  
Microglia are highly motile, which enables them to respond rapidly to a threat. Activated 
microglia exhibit an “amoeboid” shape, with an increased capacity for phagocytosis. As 
resident immune cells in the brain, apart from immune surveillance, microglial cells have 
critical physiological functions. During development, the microglia can remove excessive 
synapse growth, also known as synaptic pruning, which is crucial for neuronal development 
[69]. In addition, microglia can produce neuronal growth factors that support the survival and 
function of neurons [70].  
Studies suggest that similarly to peripheral macrophages, microglial cells can be activated in 
different directions [71], although in the in vivo situation there is a continuum between the 
M1 – M2 phenotypes, which can also overlap. Therefore, this nomenclature should not be 
interpreted or used in a binary manner. However, the M1/M2 nomenclature can be helpful 
since the phenotype of microglia is a reflection of their function, and a dominance of either of 
them can be indicative of the situation for the tissue in which they reside. Pro-inflammatory 
M1 microglia are activated to “destroy” as they produce large amounts of free radicals such 
as reactive oxygen species (ROS) and reactive nitrogen species (RNS), while anti-
inflammatory M2 microglia are activated for repair. The phenotype of the microglia is shaped 
by the surrounding microenvironment and can be viewed as a response to promote the 
homeostasis of the microenvironment. On the other hand, the products secreted by microglia 
contribute to the constitution of the microenvironment [72, 73], and can certainly perturb 
homeostasis by “over-reacting”. 
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Microglial cells have been found in the vicinity of the senile plaques [23], and are positive for 
major histocompatibility complex class II (MHC-II) and complement receptors [24, 74], 
indicating a pro-inflammatory (M1) activation. The observation that microglia surround 
senile plaques indicates that they are attracted to deal with the overabundance of Aβ, and may 
therefore play a beneficial role in AD in clearance of Aβ. However, the phagocytosis and 
clearance of Aβ by microglia appears to be insufficient in AD. Furthermore, activated 
microglia produce molecules such as pro-inflammatory cytokines and ROS that are 
detrimental for the neurons, indicating that microglia may help drive the pathogenesis of AD. 
Therefore, modulation of microglia in the way that promotes phagocytosis without causing 
pro-inflammatory activation represents a possible treatment strategy for AD. 
Misfolded Aβ can be recognized as DAMPs by microglial cells. Aβ interacts with various 
classes of PRRs, and distinct down-stream events may occur depending on which receptor 
Aβ binds to. CD36, which belongs to the scavenger receptor (SR) B family, has been 
reported to interact with fibrillar Aβ, and to induce the production of ROS, and therefore the 
activation of CD36 by Aβ is associated with a pro-inflammatory phenotype of microglia [75]. 
Complement receptor (CR) 3, also called CD11b/CD18 or macrophage antigen complex-1 
(MAC-1), belongs to the leukocyte β2-integrin receptor family, and has been found to co-
localize with senile plaques, indicating its role in clearance of Aβ [76]. CR3 has been 
reported to mediate microglial activation and ROS production in response to Aβ [77]. CD33, 
also known as siglec 3 can inhibit the phagocytosis of Aβ [78]. Notably, CD33 gene variance 
has been identified as a risk factor for AD, and increased levels of CD33 have been found in 
AD [79].  
Aβ binds to the lipoxin A4 (LXA4)/formyl peptide receptor 2 (ALX/FPR2), also called formyl 
peptide receptor-like 1 (FPRL1), forming a ligand-receptor complex that leads to 
internalization [80]. Interestingly, ALX/FPR2 also transduces an anti-inflammatory signal, as 
it binds LXA4, a mediator that plays an important role in resolution of inflammation (see 
below) [81]. 
The consequence of microglial interaction with Aβ is therefore a product of the form of Aβ 
and the expression profile of microglial Aβ-interacting proteins. 
1.2.1.1.2 Astrocytes 
Astrocytes play a supportive role for neurons and constitute up to 80% of the glial cells in the 
brain. Morphologically, astrocyte can exhibit large nuclei with thick irradiating processes 
(protoplasmic astrocytes), or smaller nuclei with thinner and longer processes (fibrous 
astrocytes). Glial fibrillary acidic protein (GFAP), a structural protein, and glutamine 
synthase, are molecular markers for astrocytes. Besides constituting a scaffold for structural 
support, protoplasmic astrocytes also play a role in removing excess neurotransmitters in the 
extracellular place, avoiding the over-excitation of postsynaptic neurons. Fibrous astrocytes 
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constitute a component of the BBB, thereby playing an important role in protecting the brain 
from the threats of peripheral origin, as well as in the transport of nutrients into the brain. 
Astrocytes also provide trophic support for neurons by producing neurotrophic factors.  
Similarly to microglia, astrocytes are activated during pathological conditions, and produce 
harmful inflammatory mediators such as cytokines and ROS [82]. Reactive astrocytes, 
exhibiting higher immunoreactivity for GFAP are found around senile plaques in the AD 
brain [83], suggested to be an early event in AD pathology [84]. Astrocytes represent the 
major source of ApoE production in the brain, also co-localized with senile plaques [85]. 
Astrocytes can be activated by Aβ, upon which they produce cytokines and ROS that cause 
neuronal injury [86].  
1.2.1.1.3 Neurons  
In general, neurons are not considered to be inflammatory cells, even though they can 
produce inflammatory cytokines in cell culture conditions [87]. Neurons can also receive and 
respond to inflammatory signals by their expression of receptors for cytokines [88]. In the 
human brain, neuronal cytokines are believed to modulate neuronal signalling and plasticity 
[89], as well as being involved in sickness behaviour [90]. In AD, neurons express surface 
molecules that can interact with Aβ, such as RAGE, which contributes to intraneuronal Aβ 
accumulation and neuronal dysfunction [80]. 
Both neurons and astrocytes can regulate microglial activation and limit excessive 
inflammation by producing signals that interact with microglia. Depending on the situation, 
both activating and inhibitory signals can be produced. The CD200 ligand (CD200L), 
produced by both neurons and astrocytes, can interact with CD200R, a cell surface 
glycoprotein that is expressed by microglia. The interaction between CD200 and CD200R 
inhibits microglial activation [91], and there is evidence that both CD200 and CD200R are 
decreased in the AD brain [92], suggesting that a lack in inhibitory signals can be a factor that 
contributes to microglial activation in AD. However, neurons and astrocytes also send signals 
that can activate microglia, e.g. the CD40 ligand (CD40L). Increased levels of CD40 and 
CD40L have been found in the AD brain, and AD patients have higher serum levels of 
sCD40 [93]. Moreover, in the presence of low levels of Aβ, the ligation between CD40 and 
CD40L can activate microglia, which then produce pro-inflammatory cytokines such as 
tumor necrosis factor (TNF)-α, which may cause damage to the neurons [94].  
1.2.1.2 Molecular components of inflammation in the brain 
Cytokines, free radicals, lipid mediators (LMs), growth factors and neurotransmitters 
constitute molecular components in inflammation, and may play a role in the inflammatory 
response in the brain. In this thesis, I will focus on cytokines and LMs. 
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Cytokines are small bioactive proteins produced by immune cells as well as other cell types. 
Important cytokines include the interleukin (IL) family, the TNF family and the interferon 
(IFN) family. The synthesis of cytokines usually requires the activation of transcription 
factors such as nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and Janus 
kinase/signal transducer and activator of transcription (JAK-STAT) in response to threats 
detected by PRRs. The cytokines can act in an endocrine, autocrine or paracrine manner. 
Upon binding to their specific receptors [95], the pro- and anti- inflammatory cytokine 
signalling pathways are activated, leading to the activation of nuclear transcription factors, 
resulting in the synthesis of these proteins.  
Cytokines play a dual role in the memory formation. It has been shown that IL-1β gene 
expression was increased during induction of long-term potentiation (LTP) both in vitro in 
hippocampal slides and in vivo in rats, and LTP maintenance was impaired by blockage of 
IL-1 receptors [96], indicating normal physiological levels of cytokines are required for 
memory formation.  In addition, studies on IL-1 receptor type I (IL-1RI) knockout mice 
showed an impairment of LTP [97], and transgenic expression of human soluble IL-1 
receptor antagonist (hsIL-1ra) was found to impair long-term memory consolidation [98]. 
However, pathophysiological levels of IL-1β have been shown to directly inhibit LTP 
invoked by tetanic stimulation in rat hippocampus [99], and affect memory consolidation in 
aged rats following bacterial infection [100]. Increased levels of IL-1β were demonstrated in 
AD brain tissue [25], and therefore memory impairment mediated by pathological levels of 
cytokines may play a role in the pathogenesis of AD.  
Increased levels of cytokines are usually interpreted as an indicator of inflammation, and 
have been proposed as potential peripheral biomarkers in the diagnosis of AD. However, 
reports on cytokine levels in mild cognitive impairment (MCI) or AD in plasma and 
cerebrospinal fluid (CSF) are inconclusive with contradicting results reviewed in [101]. The 
levels of cytokines appear to be differentially affected in AD at different stages of the disease 
pathogenesis. It has been suggested that cytokines can be classified into 3 groups, according 
to their changes with the progression of the disease [101]: steadily increasing, changed only 
during conversion period, and unchanged. Cytokines such as IL-1β, IL-6 and TNF-α 
increase steadily during the progression of the disease, whereas IL-18 and monocyte 
chemoattractant protein-1 (MCP-1) temporarily increase at the time of conversion from MCI 
to AD, and some cytokines, such as IL-1α and IL-2, remain unchanged during the disease 
progression. A standardization of cytokine measurements and patient recruitment 
characterization, together with longitudinal sampling over longer periods of time, is needed to 
better understand the role and interpretation of peripheral cytokine levels during the course of 
AD. 
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1.2.2 Involvement of inflammation in AD 
Evidence accumulated during the last three decades have shown the existence of 
inflammation in AD, including activated microglia within and surrounding senile plaques 
[23, 24], and an increase in molecules involved in the innate immunity and inflammation 
such as CR1, human leukocyte antigen (HLA)-DR [74], and IL-1 [25]. Moreover, results 
from studies employing imaging techniques that detect microglial activation [102], and from 
genome-wide association studies (GWAS), showed that gene mutations involved in 
inflammation and innate immunity such as CR1 and CD33 are associated with increased 
incidence of AD [103]. Moreover, data from in vitro studies show that Aβ can activate 
microglia and astrocytes [104, 105], leading to increased production of pro-inflammatory 
cytokines, which can increase the production of APP [35, 106, 107], and amyloidogenic 
processing of APP, resulting in increased levels of Aβ. Furthermore, inflammation is further 
potentiated by cellular debris and the microenvironment of damaged tissue. Therefore, a self-
reinforcing vicious circle has been proposed to exist in the pathogenesis of AD [35] (Fig. 1). 
Other evidence supporting the involvement of inflammation in AD has been provided by 
epidemiological studies showing that among rheumatoid arthritis patients with long-term 
Fig. 1. Reciprocal interplay between Aβ and inflammation in Alzheimer’s disease. Aβ peptide can by 
harmful for neurons by a direct action, or indirectly by activating microglia and astrocytes, which produce 
pro-inflammatory cytokines and free radicals that can damage the neurons. Inflammatory factors from 
microglia and astrocytes can stimulate the neuronal production and amyloidogenic processing of APP, 
resulting in increased levels of Aβ. Microglial cells receive regulatory signals from both neurons and 
astrocytes, and a loss of inhibitory signals contributes to microglial activation. Aβ = amyloid β. 
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medication of non-steroid anti-inflammatory drugs (NSAIDs) there was a lower incidence of 
AD [108]. However, clinical trials based on NSAIDs in patients with AD or MCI, have not 
been successful [109-111], or only beneficial in a subgroup of patients with higher baseline 
plasma levels of TNF-α and C-reactive protein (CRP) [112]. Several explanations for this 
have been suggested, such as treatment given when the pathology was already too extensive, 
too short duration of the intervention, or that the patient group was too heterogeneous. It may 
be that the beneficial effects of NSAIDs in AD only emerge in situations where a strong, 
chronic peripheral inflammation is present.  This can hypothetically be associated with a 
profile of signalling and metabolism that is different from normal, and which therefore is 
receptive to the beneficial effects of NSAIDs.  
 
1.3 RESOLUTION OF INFLAMMATION  
Inflammation is a defensive response of the body to harmful stimuli such as infection and 
injury, for the purpose of eliminating the threat, after which restorative processes take place. 
In the end, the damaged tissue is meant to be repaired and return to homeostasis. 
Inflammation is a dynamic process under strict control of regulatory mechanisms that under 
normal conditions orchestrate the progression of the response from detection, activation, 
destructive defense, and lastly to down-regulation and restoration. In addition to 
inflammatory proteins such as cytokines, lipids represent groups of molecules that are 
involved in the regulation of inflammation. For instance, prostaglandins (PGs) can cause 
vasodilatation, leading to increased blood flow at the site of injury, and “redness” and “heat”. 
PGs also mediate pain. Recent studies have shown that a group of LMs named specialized 
pro-resolving lipid mediators (SPMs) mediate the ending, or resolution, of inflammation. 
Therefore, understanding the regulation of lipid metabolism and lipid signalling in normal 
and pathological conditions is important.  
 
1.3.1 General aspects of lipids  
1.3.1.1 Lipids and the brain 
Lipids are hydrophobic or amphiphilic molecules that can be classified into several 
categories, such as glycerides, free fatty acids (FAs), sterols, phospholipids, and fat-soluble 
vitamins [113]. The bilayer structure of cellular membranes is based on lipids, which supply 
energy when metabolized to ATP [114]. Moreover, lipids are also bioactive molecules that 
play important roles in cell signalling, immune regulation and neurotransmission [115, 116]. 
Lipids account for up to 50-60% of the brain dry weight, and within the brain gray matter 
contains 36-40% lipids, white matter 49-66%, and myelin 78–81% [117]. 
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1.3.1.2 Polyunsaturated fatty acids (PUFAs) 
Polyunsaturated fatty acids (PUFAs) are FAs with more than one carbon-carbon double bond, 
classified into omega-3 (n-3) and omega-6 (n-6) FAs based on the position of this, counting 
from the first double-carbon bond from the methyl end towards the carbonyl end [118]. The 
n-3 FA family is composed of α−linolenic acid (ALA, C18:3), eicosapentaenoic acid (EPA, 
C20:5), docosapentaenoic acid (DPA, C22:5) and docosahexaenoic acid (DHA, C22:6). The 
n-6 FAs include linoleic acid (LA, C18:2), arachidonic acid (AA, C20:4), gamma-linoleic 
acid (GLA, 18:3) and dihomo-gamma-linoleic acid (DGLA, 20:3) [119]. ALA and LA are 
essential for humans, since they are required for normal physiological functions, but cannot 
be produced endogenously. Other n-3 and n-6 FAs can be converted from ALA or LA, and 
are therefore considered as “conditioned essential” [120, 121] (Fig. 2). 
1.3.1.3 Metabolism of PUFAs 
Some species of fish are enriched in PUFAs, and other dietary sources include nuts, 
sunflower oil, etc [122]. Dietary sources of lipids are absorbed and synthesized in the liver. 
Lipids can reach the brain via the blood as it has been proved that PUFAs can cross the BBB 
[123]. DHA is an important constituent of the bilayer of biological membranes, enriched in 
Fig. 2. Synthesis of DHA, EPA and AA from essential fatty acids.  
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neurons, retinoid membranes, therefore being important in neuronal function and vision. 
Lipids undergo dehydration and esterification, and can be processed to small LMs, shown to 
be important for mediating inflammation, pain, thrombosis and vascular function, etc. [117]. 
Enzymes involved in the processing of lipids include cyclooxygenases (COXs), 
lipoxygenases (LOXs) and cytochrome P450 (CYP450) [124].  
 
1.3.2 Lipid dysregulation in AD 
Lipid dysregulation is a feature of several conditions in which chronic inflammation is 
present, including obesity, vascular disease and diabetes. Interestingly, these diseases share 
many risk factors and features with AD, suggesting a complex picture of overlapping and 
interacting etiologies. A dysregulation of lipids belonging to the PUFA class is suggested by 
studies showing decreased levels of DHA in the human AD hippocampus compared to 
control subjects [125], and by dysfunctional conversion from dietary FAs to omega-3 FAs in 
the liver in AD [126]. Evidence that strongly support a dysregulation of lipids in AD is 
provided by studies focused on the polymorphisms in the ApoE gene. ApoE is a protein 
involved in cholesterol transportation and lipid metabolism [127]. It has been demonstrated 
that the E4 allele is the largest risk factor for sporadic AD [8]. In AD, ApoE is associated 
with senile plaques [128], however, the total levels of ApoE were found to be decreased in 
AD compared to controls [129, 130]. Interestingly, in AD patients given a single dose of 
uniformly 13C-labelled DHA supplementation, the clearance of DHA in plasma was slower in 
ApoE4 carriers than in non-carriers [131]. Furthermore, the ApoE4 genotype is associated 
with higher lipid peroxidation [132], which can cause oxidative stress.  
Lipid rafts are microdomains rich in sphingolipids, cholesterol and saturated FAs, and play an 
important role in cell signalling, and are crucial for neuronal functions. Lipid dysregulation in 
AD is indicated by an altered lipid profile in lipid rafts in the brain [133]. Lipid rafts are also 
involved in APP-processing, and it has been suggested that APP inside lipid rafts is processed 
by β-secretase, while APP outside lipid rafts is processed by α-secretase [134]. The 
alterations in lipid rafts may therefore hypothetically promote amyloidogenic processing of 
APP, and thus increased levels of Aβ. Moreover, there is evidence for alterations in enzymes 
involved in FA-processing in the brain, including COXs, 5-LOX and 15-LOX [135, 136].  
Furthermore, the mRNA levels for both PGD synthase and the receptor for PGD2 (DP) were 
increased in glial cells associated with senile plaques in brains from AD patients, as well as 
from a mouse model of AD [137]. PGD2 has been shown to contribute to neurotoxicity 
mediated by microglia exposed to Aβ42 and prion proteins [138]. In addition, altered levels of 
receptors for LMs, such as peroxisome proliferator-activated receptor (PPAR)-γ that receives 
and conduct lipid signalling, have been showed in AD [136, 137]. Rebalancing and restoring 
this altered lipid metabolism seen in AD may have beneficial effects. 
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1.3.3 Specialized pro-resolving lipid mediators (SPMs) 
          
Since inflammation is a protective but potentially self-destructive biological response, it 
should be ended by resolution after the pathogen is eliminated. Inflammation has commonly 
been viewed to end by a passive dissipation of the inflammatory mediators. However, 
accumulating evidence support that the resolution of inflammation is a highly regulated 
process [124]. Using a liquid chromatography tandem mass spectrometry (LC-MS-MS) 
technique, a new group of LMs were discovered, the levels of which were found to be 
increased at the later phase of inflammation [139-141]. The chemical structures of these 
molecules have been elucidated and their biological functions are under investigation, the 
work in this thesis is a part of that effort. The molecules were named SPMs, and 4 classes 
have been identified so far. They include LXA4, which is derived from AA, the D-series 
resolvins, protectins and maresins derived from DHA, and the E-series resolvins derived from 
EPA [124, 142, 143] (see Fig. 3). 
The ideal outcome of inflammation is a complete resolution, meaning that the pathogenic 
threat has to be cleared, and that the damaged tissue returns to normal, i.e. a return to 
homeostasis. However, under pathological conditions, inflammation may persist and lead to 
chronic inflammation. Chronic inflammation can be a consequence of deficiency in the 
resolution mechanism. A self-limiting inflammatory response normally occurs, where pro-
resolving activities are sufficient to counteract the pro-inflammatory response. However, in 
Fig. 3. Synthesis of SPMs from PUFAs. AA = arachidonic acid, CYP450 = cytochrome P450, 
DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, LOX= lipoxygenase, LXA4 = lipoxin 
A4, MaR1 = maresin 1, PD1 = protectin D1, PUFA = polyunsaturated fatty acid， RvD1 = 
resolvin D1, RvE1 = resolvin E1, SPMs = specialized pro-resolving lipid mediators. 
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the situation of a chronic inflammatory disease, pro-resolving activities are not sufficient to 
counteract the pro-inflammatory signalling, leading to persistent inflammation which may 
lead to chronic inflammatory disease.  
A deficiency in resolution has been described in chronic inflammatory diseases including 
AD. In patients with severe asthma, a chronic inflammatory airway allergic disease, the levels 
of LXA4 and neuroprotectin (NP) D1were found to be reduced [144, 145], and lower plasma 
levels were described in patients with localized aggressive periodontitis (LAP) compared to 
healthy individuals [146]. Reduced levels of DHA and its derivative NPD1 were 
demonstrated in the hippocampus of AD patients [125], and the LXA4 levels were lower in 
the hippocampus as well as the CSF from AD patients [136]. Furthermore, the levels of 
LXA4 and resolvin (Rv) D1 in CSF correlates with cognitive function as determined by 
MMSE [136], indicating that these SPMs may play a role in preserving memory functions.  
In light of the described deficiency in resolution in AD, it is important to understand the 
biological function of the SPMs in the brain. The biological function of SPMs in the 
periphery has been studied, but little is known so far with regard to their role and activities in 
the central nervous system (CNS). Activities of SPMs in relation to the cell type are 
summarized in Fig. 4. 
Given the beneficial functions of SPMs described above, utilizing SPMs as means to treat 
inflammatory diseases has been investigated in several models of inflammatory diseases. 
Thus, treatments with SPMs have demonstrated protective effects in models for asthma [147-
149], colitis [150, 151], and peritonitis [152, 153]. Furthermore, there is evidence of 
beneficial effects of SPMs in animal models involving the nervous system, i.e. for cerebral 
ischemia [154-158] and pain [159-163] (see Table 1). In studies on transgenic animal models 
for AD, treatment with aspirin-triggered (AT)-LXA4 was shown to ameliorate Aβ- and tau-
pathology, and to improve memory function [164, 165]. Reduced severity of eczema has 
been demonstrated in a clinical trial with 15(R/S)-methyl-LXA4 [166]. The synthetic Rv 
analogue RX-10001 has been shown to provide protection against goblet cell loss in a murine 
model of dry eye [167, 168], and RX-10001 and another Rv analogue RX-100045, have 
completed phase II clinical trials for treating dry eye syndrome. 
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Table.1. Beneficial effects of specialized pro-resolving lipid mediators (SPMs) in animal models. 
Treatment( (SPM(analogue Disease(model Effects(in(disease(model( Reference(
Corneal(
neovascularization
Reduced(inflammatory(angiogenesis( Leedom(et(al.,(2010
Stroke( Neuroprotection,(anti@inflammation Sobrado(et(al.,(2009
Attenuated(mechanical(hypersensitivity Abdelmoaty(et(al.,(
2013
(Protection(in(development(of(
nociceptive(behaviours
Sun(et(al.,(2012
LXA4ME (Stroke(
Ameliorated(BBB(dysfunction,(
neurological(dysfunctions(and(reduced(
infarction(volume(
Wu(et(al.,(2012
Ye(et(al.,(2010
ATL Alzheimer's(disease(
(AD)(
Reduced β@amyloid(pathology,(improved(
cognition
Medeiros(et(al.,(2013;(
Dunn(et(al.,(2015
ATL,(LXA4
(Cancer(induced(
bone(pain(
Attenuated(bone(caner(pain,(supressed(
inflammation(
Hu(et(al.,(2012
ATL,(3@oxa@15@epi@
LXA4(analogue(
(Allergy( Reduced(allergic(airway(responses( Levy(et(al.,(2007
An(@oxidation@
resistant
3@oxa@AT@LXA4(
analogue
Colitis( Attenuated(colitis(in(rodents( Fiorucci(et(al.,(2004
ATL(synthetic(mimetic Transplantation (Protection(in(graft@versus@host(disease Devchand(et(al.,(2005
(Pain(
LXA4
LXA4
Fig. 4. Activities of SPMs in relation to the cell type: 1) inhibition of leukocyte recruitment, 
2) stimulation of monocyte recruitment and of their differentiation into macrophages, 3) 
promoting macrophage phagocytosis of pathogens, 4) stimulation of neutrophil apoptosis, 5) 
stimulation of phagocytosis of apoptotic neutrophils (efferocytosis), and 6) modification of 
the macrophage phenotype from pro-inflammatory M1 to anti-inflammatory M2 phenotype. 
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ATL = aspirin-triggered lipoxin A4, AT-RvD = aspirin-triggered resolvin D, AT- NpD = aspirin-
triggered neuroprotein D, LXA4 = lipoxin A4, LXA4ME = lipoxin A4 methyl ester, NpD = 
neuroprotein D, 3-oxa-15-epi-LXA4 = 5S,6R,7E,9E,13E,15S)-16-(4-fluorophenoxy)-3-oxa-5,6,15-
trihydroxy-7,9,13-hexadecatrien-11-ynoic acid,  RvD = resolvin D, RvE = resolvin E.  
1.3.4 Receptors for SPMs 
Although there is evidence for beneficial effects of SPMs, the underlying molecular 
mechanisms are largely unknown. Receptors for LXA4, RvD1 and RvE1 have been identified, 
while the receptors for other SPMs remain unknown. All the receptors identified so far 
belong to 7-transmembrane (7-TM) G protein-coupled receptors (GPCRs). LXA4 and RvD1 
have been found to bind to ALX/FPR2 and G protein receptor (GPR) 32 [169, 170], and 
RvE1 binds to chemerin receptor 23 (ChemR23) and the leukotriene B4 receptor 1 (BLT1) 
[153, 171]. RvE1 binds to BLT1 as a partial agonist, and counteracts pro-inflammatory 
signals transduced by BLT1 to mediate the resolution of inflammation [153]. These receptors 
bind other ligands upon which they can transduce a pro-inflammatory signal. ALX/FPR2 has 
been identified as a receptor for Aβ [172], which activates microglia, and thereby transducing 
pro-inflammatory signals. ChemR23 binds chemerin [173], a chemotactic peptide [173], 
Treatment( (SPM(analogue Disease(model Effects(in(disease(model( Reference(
Colitis Reduced,cellular,infiltration,and,colonic,
tissue,damage
Marcon,et,al.,,2013
Surgry,in,planaria Tissue,regeneration,and,pain,control Serhan,et,al.,,2012
,Peritonitis Enhanced,phagocytosis Serhan,et,al.,,2009
ATCNPD1 ,Stroke ,Attenuated,cerebral,ischemic,injury
Bazan,et,al.,,2012;,
Marcheselli,et,al.,,
2003
,,Peritonitis, ,Promoting,resolution,of,acute,
inflammation
Yamada,et,al.,,2011
,Choroidal,
neovascularization
Attenuated,leakage,and,
neovascularization
Sheets,et,al.,,2013
,Pain,induced,by,
nerve,trauma,
Prevention,of,mechanical,allodynia Rajasagi,et,al.,,2013;,
Xu,et,al.,,2013
,HSVCinduced,
corneal,stromal,
keratitis
Reduced,severity,,of,stromal,keratitis Bazan,et,al.,,2012
Lateral,paw,incision,
surgery,
Reduced,postoperative,pain, Huang,et,al.,,2011
,Wound,healing Promoted,would,healing, Tang,et,al.,,2013
Peritonitis, Attenuated,neutrophil,recruiment Norling,et,al.,,2012
,Pancreatitis, Attenuated,pain, QuanCXin,et,al.,,2012
ATCRvD1 ,Stabilized,tibia,
fracture
Reversed,signs,of,systemic,injury,and,
inflammation,
Terrando,et,al.,,2013
,RvD1,,ATCRvD1 Allergy, ,Decreased,airway,eosinophilia,and,
mucus,metaplasia
Rogerio,et,al.,,2012
RvD2 Pain, Prevented,formalinCinduced,spontaneous,
pain
Park,et,al.,,2011
RvD3,,ATCRvD3 Peritonitis, Proresolving,actions Dalli,et,al.,,2013
RvE1,,RvD1 Fibrosis,caused,by,
ureteric,obstruction
Inhibitition,of,interstitial,fibrosis,in,
obstructed,kidney
Qu,et,al.,,2012
,Asthma,
Decreased,airway
eosinophil,and,lymphocyte,recruitment,,
downCregulated,Th2,cytokines,,and,
decreased,airway,hyperresponsiveness
Aoki,et,al.,,2008
,Acute,lung,injury ,Promoted,neutrophil,apoptosis,,
enhanced,resolution,in,lung
El,Kebir,et,al.,,2012
,Peritonitis Reduced,neutrophil,infiltration Arita,et,al.,,2007
Asthma ,Inhibition,of,allergic,pulmonary,
inﬂammation
Flesher,et,al.,,2014
RvD1
RvE1
NPD
Resolvin
Maresin1 Maresin1
NPD1
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associated with increased inflammation [174]. Furthermore, the nuclear receptor PPAR-γ has 
been reported to mediate protective effects of SPMs [175]. GPR120 binds long chain FAs 
including DHA and EPA [176], and may also be a candidate receptor for SPMs.  
In a recent study, alterations in the expression of receptors for SPMs have been demonstrated 
in the AD brain [136]. In the human brain, both neurons and glial cells express ChemR23, 
with higher levels found in AD compared to control subjects [136]. Similar to ChemR23, 
ALX/FPR2 was described to occur in both neurons and glia in the human brain, with higher 
levels in AD [136]. Furthermore, the levels of PPAR-γ were higher in the hippocampus of 
AD patients [136]. The increased levels of SPM receptors in the AD brain may be interpreted 
as a compensatory mechanism for the reduced levels of SPMs [136]. Interestingly, at least 
some of the anti-inflammatory effects of SPMs seem to be due to competition of SPMs with 
pro-inflammatory ligands such as LTB4, acting as partial agonists or antagonists [153]. The 
plurality of ligands with pro-inflammatory effects, and the increased levels of SPM receptors 
in AD brains can therefore also be interpreted as a feature of the pronounced chronic 
inflammatory state in the AD brain.  
 
1.3.5 Enzymes involved in the resolution of inflammation  
The SPMs are synthesized from their PUFA precursors via the activities of LOXs and COXs. 
LOXs add oxygen to the carbon chain of PUFAs, and depending on the site of incorporation 
the enzyme was classified as 5- or 15-LOX [177]. Notably, besides the role in synthesis of 
SPMs, 5-LOX is also involved in the synthesis of pro-inflammatory leukotrienes (LTs). 
COXs are crucial enzymes involved in the synthesis of PGs, which mediate inflammation and 
pain (Fig. 5). Interestingly, COXs together with LOXs can give rise to aspirin-triggered (AT) 
forms of SPMs in response to aspirin. Thus, the production profile of LMs by this enzymatic 
machinery can change from pro-inflammatory classes of LMs to pro-resolving classes of 
Fig. 5. Synthesis of lipid mediators from AA. AA = arachidonic acid, CysLTs = cysteinyl 
leukotrienes, 5-HETE = 5-hydroxy-6E, 8Z, 11Z, 14Z-eicosatetraenoic acid, 15-HETE = 15-
hydroxy-5Z, 8Z, 11Z, 13E-eicosatetraenoic acid, 15-HPETE = 15-hydroperoxy-5Z, 8Z, 
1Z, 13E-eicosatetraenoic acid, LT = leukotriene, LX = lipoxin, PG = prostaglandin, TX = 
thromboxane. 
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LMs, a process termed “class-switching”. Increased knowledge on the activation and 
regulatory mechanisms of these enzymes, and how this can prevent or result in class-
switching, is necessary to increase the understanding of chronic inflammatory diseases, and 
how tissue regeneration may be stimulated. 
1.3.5.1 5-LOX 
5-LOX is encoded by the gene ALOX, which is located in chromosome 6. In the brain, 5-
LOX is expressed by all types of cells [178], and higher levels have been shown in AD brains 
as well as in an AD mouse model [135]. Crossing 5-LOX knockout mice with a mouse model 
for AD, based on transgenic expression of mutated human APP, resulted in reduced Aβ 
pathology and improved cognitive performance [179]. The tetracycline antibiotic 
minocycline inhibits 5-LOX, and has been used for the treatment of asthma. Interestingly, 
minocycline has been shown to inhibit BACE1, and reduce Aβ pathology and inflammation 
in APP transgenic mice [180]. 5-LOX is activated by phosphorylation at three currently 
known sites, Ser663, Ser271 and Ser523. Ser271 is phosphorylated by P38 mitogen-activated 
protein kinase (MAPK), and extracellular-signal-regulated kinases (ERK) phosphorylate 5-
LOX at Ser663 [181]. Interestingly, phosphorylation of 5-LOX at Ser523 has been reported 
to shift the production of LMs toward LXA4, while the production of LTB4 is decreased, and 
Ser523 is therefore considered to be an anti-inflammatory phosphorylation site, that is 
involved in class-switching [182, 183]. 5-LOX is irreversibly inactivated by its end products, 
such as LTB4. 
1.3.5.2 15-LOX-1 and 15-LOX-2  
Two isoforms of 15-LOXs can be found in the brain: 15-LOX-1 and 15-LOX-2 [136, 184]. 
15-LOX-1 is also been referred to as 12/15 LOX due to they can oxygenate AA at both C12 
and C15 position [185].  15-LOXs are implicated in many diseases including AD [186]. It has 
been reported that in the AD brain, in pathologically affected areas such as frontal and 
temporal region, the levels of 15-LOX-1 were higher, and its metabolic products 15-
hydroxyeicosatetraenoic acids (15-HETE), were also markedly elevated in the CSF of AD 
patients compared to controls [184, 187]. Increased levels of 15-LOX-2 were reported in the 
hippocampus as well [136]. Interestingly, decreased levels of both 15-LOX-1 and15-LOX-2 
were observed in cancer [188, 189], and in vitro overexpression of 15-LOX-1 in colorectal 
cells inhibits cell growth and induces apoptosis [190, 191]. It has been suggested that the 
balance between 15-LOX-1 and 15-LOX-2 is important. For instance, the shift in expression 
from 15-LOX-2 to 15-LOX-1 is associated with neoplastic progression [192]. The role of 15-
LOXs in AD is unclear, since 15-LOXs can directly oxidize lipids in the cell membrane 
[193], generating oxidative stress that can be detrimental for the neurons. However, 15-LOXs 
are also involved in the synthesis SPMs, and thus related to anti-inflammatory and pro-
resolving activities. In addition, the anti-inflammatory cytokines IL-4 and IL-13 induce the 
expression of 15-LOX-1 [194]. Inhibition of 15-LOX-1 in APP-overexpressing 
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neuroblastoma cells significantly reduced the levels of soluble APPβ and β-secretase (BACE) 
[195]. Moreover, crossing APP transgenic mice with 15-LOX knockout mice resulted in a 
progeny with reduced Aβ pathology [196]. To summarize, 15-LOX may play a dual role in 
AD, but further studies are needed to elucidate the biology of this enzyme and how it is 
regulated. 
1.3.5.3 COX-1 and COX-2  
The genes encoding COX-1 and COX-2 are located on chromosome 9 and 1, respectively. In 
a study where the authors stained frontal and temporal brain tissue from post-mortem AD and 
control subjects by immunohistochemistry, COX-1 immunoreactivity was found both in 
neurons and microglial cells, while COX-2 immunoreactivity was found only in neurons, and 
the number of COX-2 positive neurons were increased in AD brains compared to control 
brains [197]. Later studies have shown increased levels of COX-2 at early stages of AD, 
whereas decreased levels were observed at a late stage [198, 199]. Aspirin, which is a well-
known NSAID, widely used for treatment of inflammation. Low doses of aspirin are 
prescribed for the prevention of cardiovascular events. The mechanism of action for aspirin is 
through irreversible acetylation of COX-1 and COX-2 and thereby affecting its catalytic 
activity and inhibiting the synthesis of PGs and thromboxanes (TXs) [200]. Interestingly, 
aspirin was found to trigger transcellular formation of a novel series of aspirin-triggered 
lipoxins (ATLs) during co-incubation of human umbilical vein endothelial cells with 
neutrophils [201]. Later studies showed that ATLs inhibited the neutrophil infiltration in a 
mouse ear inflammation model, showing anti-inflammatory and pro-resolving properties 
[81]. Further studies on the mechanisms of ATL synthesis showed that acetylated COX-2 is 
still active and can convert AA to 15-RHETE and give rise to ATL [202].  
 
1.3.6 Class-switching 
Signals that can promote class-switching represent another pathway for stimulating resolution 
of inflammation, but need further investigation. Acetylcholine (ACh) has been suggested to 
be involved in the class-switching mechanisms. ACh is a neurotransmitter that is involved in 
memory and learning [203], and the degeneration of cholinergic neurons in the AD brain is a 
major part of the neuropathology, and the basis for symptomatic treatment with 
cholinesterase inhibitors (ChEIs). Furthermore, there is a loss of cholinergic receptors in the 
cerebral cortex of AD patients [204-206]. Aβ can bind with high affinity to the α7 nicotinic 
cholinergic receptor (α7nAChR) in neurons [207], thus impairing the ability to be activated 
by ACh [208]. α7nAChRs are also expressed by microglia, and ACh inhibits microglial 
activation [209]. It has been reported that activation of α7nAChR in microglia by nicotine 
reduced lipopolysaccharide (LPS)-induced production of the pro-inflammatory cytokines 
TNF-α and IL-18 [210], indicating an anti-inflammatory effect of ACh. However, ACh also 
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increases COX-2 and the classical pro-inflammatory LM PGE2 [211]. Interestingly, exposure 
of human blood neutrophils to PGE2 increased the production of the pro-resolving LXA4, 
while reducing the anti-inflammatory LTB4, indicating a role of PGE2 in class-switching 
between LMs [212]. Thus, the anti-inflammatory effect of activation of a7nAChR may be 
due to class-switching through PGE2. However, the direct effect of a7nAChR activation on 
LOX enzymes and SPM production has not yet been investigated, but is of great interest. 
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2 AIMS 
The main aim of this thesis was to investigate the role of resolution of inflammation in AD, 
and whether stimulation of resolution of inflammation can be a novel therapy for AD. 
 
The specific aims were to investigate:  
 
Paper I: the effects of DHA and EPA on microglial phagocytosis of Aβ on secreted and 
cellular markers of immune activity. 
 
Paper II:  whether Aβ, the major component of senile plaques in the AD brain, may have 
a negative influence on components of the resolution cascade. 
 
Paper III: possible alterations in SPMs in the entorhinal cortex (ENT) using LC-MS-MS, 
and the actions of SPMs in AD-related in vitro models.  
 
Paper IV: the effects of n-3 FA supplementation on the release of SPMs in relation to 
ApoE4 genotype in AD patients. 
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3 MATERIALS AND METHODS 
3.1 CLINICAL SAMPLES 
3.1.1 Post-mortem human brain samples  
Post-mortem analysis of brain pathology is the golden standard for AD diagnosis. 
Furthermore, post-mortem brain samples provide valuable research material for 
understanding the underlying pathology and mechanisms.  
 
3.1.2 Plasma samples  
The collection of CSF is an invasive procedure. Therefore, blood-based biomarkers are of 
great interest for the diagnosis of AD. So far, no single reliable blood-based biomarker has 
been identified for AD. Probably, a combination of several biomarkers will be required to 
predict AD with sufficient sensitivity and specificity.  
 
3.2 CELLULAR MODELS 
3.2.1 Human microglial cell line  
3.2.1.1 General characteristics  
The human microglial cell line CHME-3 was derived from 8-10 weeks old embryonic human 
microglia transfected by plasmid-containing cDNA encoding SV40 T antigen [213]. The 
CHME-3 cells maintain certain properties of primary microglial cells, such as phagocytosis, 
and the expression and secretion of immune molecules in response to inflammation induced 
by LPS and Aβ that have been demonstrated by the authors in the work in this thesis. 
However, compared to primary microglia, the CHME-3 cells spontaneously secrete IL-6, 
providing stimulatory signals at basic culture conditions. Furthermore, the phagocytic 
capacity of the CHME3 cells appears to be lower than in primary microglia, possibly a result 
of the chronic IL-6 stimulation. The CHME-3 cells are heterogeneous with regard to size and 
morphology. During control conditions, the CHME-3 cells express both pro-inflammatory 
M1 markers such as CD40 and CD86, and anti-inflammatory M2 markers such as CD163 
and CD206. We have shown that activation of CHME-3 cells with Aβ42 leads to increased 
levels of M1 markers and increased secretion of TNF-α (Paper III). 
 
 26 
3.2.1.2 Resolution pathway in CHME-3 cells 
CHME-3 cells express receptors to SPMs, including ALX/FPR2, GPR32 and ChemR23 (Fig. 
6A-C). CHME-3 cells also possess the enzymatic machinery (COX, 5-LOX, 15-LOX) that is 
needed for the synthesis of SPMs. We have shown that CHME-3 cells can secrete the SPMs 
LXA4 and RvD1 in culture. Therefore, in human brain, microglial cells can be a source of 
SPMs. However, this does not exclude other cell types as sources of SPMs in the brain. 
3.2.2 Human neuroblastoma cell line  
3.2.2.1 General characteristics  
The human neuroblastoma SH-SY5Y cell line is a sub-line of SK-N-SH cells, which were 
derived from the biopsy from a metastatic neuroblastoma patient in the 1970s [214].  The SK-
N-SH cells have three subtypes: neuronal (“N” type), Schwanninan (“S” type) and 
intermediate (“I” type) [215]. The SH-SY5Y cell line mainly contains cells of the N type. The 
cells have been shown to be dopaminergic, adrenergic, cholinergic and glutamatergic, and are 
therefore widely used as a neuronal model for Parkinson’s disease (PD) and AD. SH-SY5Y 
cells are neoplastic and possess stem cell properties, and can be differentiated by various 
agents such as retinoic acid (RA), 12-tetradecanoyl-13-acetyl-beta-phorbol (TPA), growth 
factors and vitamin D3, to become more similar to mature neurons. Morphologically, 
undifferentiated SH-SY5Y cells have multiple short spiny processes (Fig. 7A).  
Fig. 6. SPM receptors in human microglia. A) ChemR23: receptor for RvE1. B) ALX/FPR2: 
receptor for LXA4 and RvD1. C) GPR32: receptor for LXA4 and RvD1. ALX/FPR2 = lipoxin A4 
(LXA4)/formyl peptide receptor 2, ChemR23 = chemerin receptor 23, GPR32 = G protein-coupled 
receptor 32, LXA4 = lipoxin A4, RvD1 = resolvin D1, RvE1 = resolvin E1. SPMs = specialized 
pro-resolving lipid mediators.  
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In this thesis, differentiated SH-SY5Y cells were used, obtained by sequential treatment with 
RA for 5 days and brain-derived neurotrophic factor (BDNF) for another 5 days. Upon 
treatment with RA, the cells become elongated and begin to extend processes to some degree, 
while continuing to divide and proliferate. After switching to serum-free medium containing 
BDNF, the proliferation stops and the cell bodies decrease in size and gradually extend long, 
extensively branched neurites (Fig. 7B-D), showing a morphology similar to that of primary 
neurons. Differentiated SH-SY5Y cells also have more mature neuronal molecular 
characteristics compared with undifferentiated cells, exemplified by an increase in 
cholinergic markers, and mature isoforms of tau protein [216], which makes them suitable for 
experiments related to AD, as compared to undifferentiated cells. Another important 
advantage of the differentiated cells is that they stop dividing upon switching to serum-free 
medium, thereby avoiding confounding effects of cell division, which is major drawback of 
continuously dividing cell lines.  
 
 
Fig. 7. Differentiation of SH-SY5Y neuroblastoma cells. A) Undifferentiated cells. B) Cells incubated 
with RA for 24 h. C) Cells incubated with RA for 5 days. D) Cells incubated with BDNF for 2 days, 
following the 5 days of incubation with RA. BDNF = brain-derived neurotrophic factor, RA = retinoic 
acid. 
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3.2.2.2 Resolution pathway in SH-SY5Y cells  
 SH-SY5Y cells differentiated with RA and BDNF express receptors to SPMs, i.e. 
ALX/FPR2 and GPR32, which are receptors for LXA4 and RvD1 (Fig. 8A and C), as well as 
ChemR23 and BLT1, which are receptors for RvE1 (Fig. 8B and D). Therefore, differentiated 
SH-SY5Y cells are able to receive signals of the resolution pathway, supporting its use as a 
neuronal model in studies on resolution of inflammation.   
 
3.2.3 Advantages and disadvantages of using cell lines vs. primary cultures  
3.2.3.1 Advantages  
Cell lines are continuously dividing cells that can be passaged many times, and can therefore 
provide an almost unlimited source of cells for experiments. Compared to primary cultures, 
Fig. 8. SPM receptors in human differentiated neuroblastoma cells. Micrographs show SH-SY5Y 
neuroblastoma cells differentiated with RA and BDNF. A) ALX/FPR2: receptor for LXA4 and 
RvD1. B) ChemR23: receptor for RvE1. C) GPR32: receptor for LXA4 and RvD1. D) BLT1 
receptor for RvE1 and LTB4. ALX/FPR2 = lipoxin A4 (LXA4)/formyl peptide receptor 2, BDNF = 
brain-derived neurotrophic factor, BLT1 = leukotriene B4 receptor type I, ChemR23 = chemerin 
receptor 23, GPR32 = G protein receptor 32, LXA4 = lipoxin A4, RA = retinoic acid, RvD1 = 
resolvin D1, RvE1 = resolvin E1. SPMs = specialized pro-resolving lipid mediators. 
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cell lines are also easier to culture - primary cultures usually require more supplements to the 
medium, are less resilient, and have a higher risk of contamination. Many cell lines are 
commercially available and have been well characterized, enabling interpretation and 
comparison of results from different laboratories using the same cell line. Primary cells 
derived from patients can behave differently depending on the genetics, age and origin, and 
most of them are less well characterized, making it difficult to compare results from different 
laboratories.  
3.2.3.2 Disadvantages  
Cell lines are artificially or naturally or artificially immortalized cells that escape the normal 
cellular senescence, and are therefore continuously dividing. Compared to primary cells, the 
responses of a cell line can be less similar to the in vivo situation. In particular, the rapid 
proliferation often seen in cell lines can be a confounding factor, especially when studying 
toxicity and the protection against this. Because of the genetic modification and the loss of 
normal genome integrity, the cells of a cell line have a higher rate of gene mutations and may 
therefore change their original phenotype, resulting in the loss of genes relevant to the 
research question, or result in different and even contradicting responses to the same stimuli 
between passages. Therefore, it has been suggested to use a limited number of passages for 
cell biological research. Or if not possible, perform continuous characterization of the cell 
line upon growing passage number.  
 
3.3 TECHNIQUES  
3.3.1 Flow-cytometry  
Flow-cytometry is a technique that is widely used in research and clinical practice for 
immune phenotype analysis. It is a powerful technique that simultaneously analyses multiple 
physical characteristics of cells as they flow in a fluid stream through a beam of laser light, 
while at the same time allowing immunocytochemical detection by several fluorophore-
conjugated antibodies directed at the respective antigen, the number being limited by the laser 
and filter characteristics of the flow-cytometer. The characteristics including size, internal 
complexity and relative fluorescence intensity, can be determined by an optical-to-electronic 
coupling system. Flow-cytometry is widely used for the diagnosis of blood cancers. It is also 
used for cell cycle analysis, and cell sorting for selection and purification of cells. 
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3.3.2 Enzyme-linked immunosorbent assay (ELISA)  
3.3.2.1 Sandwich ELISA 
Also named indirect ELISA, which is the most common type of ELISA being used in 
research. A capture antibody is bound to the plastic surface in the wells of a multi-well plate. 
Before the antigen is applied the surface is blocked with an inert protein such as bovine 
serum albumin (BSA), to decrease unspecific binding of the antigen to the surface of the well. 
The sample containing the antigen of interest is incubated in the well, allowing it to bind to 
the antibody. Next, an enzyme-conjugated secondary antibody specific to another epitope of 
the antigen is added, thereby ‘locking’ the antigen between the capture and secondary 
antibody, and hence the name “sandwich ELISA”. A substrate for the conjugated enzyme is 
added, and the resulting product is detected by absorbance, fluorescence or 
chemiluminescence. It is a method with high sensitivity; however the specificity of the 
ELISA is dependent on the quality of the antibodies.  
3.3.2.2 Competitive enzyme immunoassay (EIA) – for analysis of lipid mediators 
The LMs LXA4, RvD1 and LTB4 were analysed in the cell culture medium and human 
samples using EIA, which is a technique based on competitive binding between the antigen in 
the sample and an enzyme-conjugated antigen that is added to the sample. Conjugated 
antigen competes with the antigen in the sample for the primary antibody binding sites. 
Therefore, the signal derived from the enzymatic reaction is inversely proportional to the 
amount of free antigen in the well during incubation. 
 
3.3.3 Immunohistochemistry  
Immunohistochemistry, or immunocytochemistry in the case of cell cultures, is a classical 
and useful technique to investigate the presence and location of a specific antigen in tissue or 
cells by using a specific antibody that binds to the antigen, thereby allowing visualization 
under a microscope. The information obtained is both qualitative morphological and 
quantitative. By using image analysis software, it is possible to determine the approximate 
levels of an antigen. Similarly to ELISA and to all methods employing antibodies, the quality 
and specificity of the antibody is determinant of the quality of the output data. 
 
3.3.4 Western blot  
Western blot is a technique involving gel electrophoresis and immunoblotting. 
Electrophoresis separates the denatured proteins by the molecular weight of the protein. The 
addition of sodium dodecyl sulphate (SDS), an anionic surfactant that disrupts non-covalent 
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bonds and denatures proteins, results in a charge that is proportional to the size of the protein, 
independent of the charge of the amino acids. The protein thereby travels in the electrical 
field through the gel, which offers physical resistance, with a speed that is proportional to its 
size, resulting in separation in the gel according to size. Subsequently, the proteins are 
transferred to a nitrocellulose membrane and stained with antibodies specific for the protein 
of interest. Compared to immunohistochemistry, it is more specific due to additional 
information offered by size separation. It is also easier to quantify. In addition, in some 
situations, it can give some information regarding post-translational modification 
(phosphorylation, glycosylation), or aggregation form (dimerization, etc.), according to the 
molecular weight of the protein. A disadvantage is the lack of information on morphological 
cellular localization. 
 
3.3.5 Lipid chromatography – tandem-mass spectrometry (LC-MS-MS)  
Lipids are of crucial importance for their involvement in biological and pathophysiological 
process, hence knowing the composition and concentration of lipid metabolites in biological 
samples will expand our knowledge and understanding of a disease. However, due to the 
diversity of the structural and physical properties of lipids, analysis of wide-scale lipid 
profiles has been considered difficult. With the development of new purification systems and 
advanced mass spectrometry (MS) techniques, it is now possible to analyze and quantify 
lipids with accuracy in a large scale. Lipid chromatography (LC) enables separation of lipids 
in a biological sample, allowing a subsequent advanced MS analysis. Briefly, samples are 
prepared in a pH-adjusted water-organic mixture (mobile phase), and then forced through a 
column (stationary phase) in order to accomplish a particular type of separation. MS is based 
on the analysis of mass-to-charge ratio of the charged particles. It is a powerful technique to 
determine the mass, composition and chemical structure of a sample or molecule. In the MS 
instrument the sample undergoes vaporization for ionization to generate charged molecules, 
and then the ions are separated according to their mass-to-charge ratio by electromagnetic 
fields. The ions are detected and the signals are presented in mass spectra. MS technique is 
both qualitative and quantitative, and can be used to identify an unknown molecule or 
quantify the concentration of a known molecule in a sample.  
 
3.3.6 Measurement of cell viability and death 
3.3.6.1 Resazurin assay 
The resazurin assay (also known as Alamar Blue assay) is a widely used method for analysis 
of viability of mammalian cells and bacteria. Living cells are metabolically active, and the 
non-fluorescence resazurin dye is reduced in the mitochondria of living cells by a reducing 
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enzyme to resorufin, a fluorescent compound. The fluorescence signal is proportional to the 
number of viable cells. The resazurin assay correlates well with another commonly used 
assay based on formazan, the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay, but it is safer and easier to use, and we have also found it to be more 
sensitive. In addition, it is not toxic for the cells, allowing long-term incubation and other 
subsequent applications. 
3.3.6.2 Lactate dehydrogenase (LDH) assay  
Lactate dehydrogenase (LDH) is an enzyme present in all types of cells, and it leaks out 
through the broken plasma membrane in damaged cells. The LDH assay is a sensitive, 
convenient and precise assay based on the oxidization of lactate to pyruvate by LDH released 
to the culture medium. The resulting pyruvate reacts with a tetrazolium salt (INT, 2-(4-
iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium) to form formazan, which has an 
orange colour. The strength of the signal from the colorimetric reaction in the culture medium 
is proportional to the number of lysed (dead) cells in the culture.   
 
3.4 STATISTICS  
3.4.1 Multivariate analysis (MVA) 
MVA analysis was used in Paper II and IV in the thesis. MVA is a powerful statistical 
method that analyses all variables together. It gives information about the overall pattern of 
the data such as clustering and class separation. It has been widely used for analysis of 
databases that include many variables, such as in the “omics” fields. It is also useful for 
experimental data with fewer variables, since it may provide a better interpretation of the 
data.  
The principle of MVA is to reduce the dimensionality (equals to number of variables) of the 
data and focus on the information of interest into several latent variables (equals to the 
number of components of the model), similar to how shadows of a multi-dimensional cloud 
of variable spots can be projected onto a plane [217]. Compared to univariate analysis, MVA 
also avoids type I and type II errors by avoiding doing multiple comparison analysis. The 
MVA in this thesis were performed using the SIMCA P+ software package (UMETRICS 
AB, Umeå, Sweden). 
Principle component analysis (PCA) is a statistical method that used to examine the 
interrelations among a set of variables in order to identify the underlying structure of those 
variables, so that similar samples clustered together and distinct samples far apart. PCA is the 
basis of all MVA analysis. It is an unsupervised non-parametric analysis method that is 
independent of any hypothesis about data distribution, and gives an overview about the 
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structure (patterns of similarities in the observations) of the data. PCA is based on projection 
of the high dimensional data to principle components (PCs), and each principle component 
can be viewed as one latent variable that describes the information extracted from the dataset: 
the first principle component (PC1) finds the largest variance of the data set comes to lie on 
the first axis, and the PC2 find the second largest variance comes to line on the second axis, 
which is orthogonal to the first axis. Subsequently, next PC will find the next largest variation 
and comes to lie on the next axis that is orthogonal to the previous one. 
Orthogonal projections to latent structures (OPLS) is a prediction and regression method that 
finds the association between the quantitative X data that is related to known information, the 
Y data. Therefore, it is a supervised analysis method. In OPLS, the X data are separated into 
two components based on their association with the Y data: predictive component describes 
information that are correlated to the Y data and orthogonal component that describes the 
information that are not related to the Y data. If the Y data are composed of discrete 
variables, which may indicate for example treatment or diagnostic groups, the analysis is 
called OPLS- DA (discriminant analysis). The ease of interpretation is an advantage of 
OPLS-DA, since it shows which variables are responsible for class discrimination. The 
degree of contribution of each variable for the class separation can be obtained by analysing 
correlations between predictive X data and Y data, and visualized in the loading plot.  
The quality of MVA can be determined using the following parameters: R2 estimates the 
goodness of fit and indicates how well the model explains the dataset. In OPLS-DA, the R2X 
value for the predictive components represents the fraction of variation in X related to 
variation not related to Y. A low R2X value for the predictive component indicates that X 
contains much variation not related to Y. The R2Y value is the correlation between the 
measured and predicted Y values and gives an indication how well the model describes the 
response. Q2 values give information about predictive ability based on cross validation, which 
is a model validation technique for assessing how the results of a statistical accurately a 
predictive model will perform in practice.  
 
3.4.2 Univariate analysis  
The univariate analyses were performed by IBM SPSS statistics 20.0 software (IBM 
Corporation, NY, USA) or Statistica 12 (Dell Software, Aliso Viejo, USA).  
For in vitro studies, the data were normalized to the average of that particular experiment 
(Paper I, II and III). The data were logarithmized to allow for parametric statistical analysis 
(Paper I). Normally distributed data were analysed by one-way ANOVA followed by 
Fisher’s post hoc test (Paper I), whereas non-normally distributed data were analysed by the 
Mann-Whitney or the Kruskal-Wallis test (Paper II – IV). For dependent variables, non-
parametric Wilcoxon matched-pairs test were used (Paper I, IV). Correlation analysis was 
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performed with the non-parametric Spearman’s rho test (Paper IV). For all the studies, 95% 
confidence interval and p-values < 0.05 was used to indicate statistical significance. 
 
4 ETHICAL CONSIDERATIONS 
The use of human CSF and post-mortem brain samples was approved by the ethical 
committee at Karolinska Institutet, the regional human ethics committee of the Stockholm 
County, and the Swedish Ministry of Health and Social Affairs. The ethical permit numbers 
are: 2011/680-31/1 for the human CSF samples, and Dnr 024/01 and 2011/962-31/1 for 
human post-mortem brain tissues.
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5 RESULTS AND DISCUSSION 
5.1 FORMS OF Aβ, AGGREGATION AND PHAGOCYTOSIS 
5.1.1 Aβ species 
In Paper I, II and III, we treated human microglia cells with different concentrations of 
Aβ42. For the studies on phagocytosis of Aβ42 we used 1µg/ml (0.22 µM), and for 
investigating the effects on microglial activation and inflammation 1-100 µg/ml (0.22 – 22 
µM) of Aβ42 was used. The choice to use Aβ42 over other species of lengths of Aβ for our 
studies was motivated by the evidence indicating that Aβ42 is the species most associated 
with the pathology in AD. 
 
5.1.2 Concentration of Aβ42 
It is difficult to determine which concentration of Aβ42 to be used in in vitro studies where the 
culture conditions is supposed to be as similar as possible to the situation in the human AD 
brain. The concentrations of Aβ42 in the AD brain may depend on the region, and it is 
plausible that the concentration around the senile plaques is higher than in other areas. The 
post-mortem time can also influence the levels. Most in vitro studies have used a µM range 
for studies on the toxicity of Aβ42 in neuronal models, and this has been criticised as being 
higher than physiological concentrations, suggested to be in the pM range in the human brain 
[27, 218, 219]. Although concentrations in the µM range are commonly used to induce 
toxicity in neuronal in vitro models, the concentration required is dependent on the parameter 
chosen for indicating toxicity. Lower concentrations of Aβ that do not reduce cell viability 
may still cause impairment in synaptic function. Furthermore, the effects of Aβ in cellular 
experiments can only mimic acute toxicity of Aβ, while Aβ accumulation in in vivo 
conditions in AD patients may have occurred decades before the onset of clinical symptoms 
[220, 221]. Therefore, results from studies on neurotoxicity of Aβ42 and treatments offering 
protection against this are difficult to translate to the situation in the human brain. 
 
5.1.3 Aggregation of Aβ42 
In Papers I and III, we characterized the aggregation form of Aβ42 at different times of 
incubation in cell culture medium (Paper I: incubation with 1 and 5 µg/ml Aβ42 for 0, 6 and 
24 hours; Paper III: incubation with 0, 10 and 100 µg/ml Aβ42 for 24 hours), using western 
blot and thioflavin T (ThT) assay. The results showed that in our experimental conditions, at 
1 µg/ml, there is no detectable band as measured by western blot. The total amount of protein 
loaded at 1 µg/ml was 75 ng, which may be too low for detection by western blot. However, 
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the concentrations of 5, 10 and 100 µg/ml resulted in detectable levels after 6 and 24 hours 
incubation, showing bands in the western blots for of a mixture of monomers, dimers, and 
oligomeric forms of Aβ42 in the culture medium. At 1 and 5 µM, fibrillar forms of Aβ42 were 
detected by the ThT assay. It is reasonable to assume that higher concentrations of Aβ42 
correlate to the density of the band, and to the fluorescence signal determined by the ThT 
assay. However, the aggregation of Aβ42 is also dependent on concentration [222], making 
comparisons between different concentrations of Aβ42 in relation to their aggregational form 
difficult. 
To analyse the aggregational forms of Aβ42 at the time of harvesting the cells, the cross-linker 
glutaraldehyde was used, in order to ‘freeze’ the forms of Aβ42. As shown previously [223], 
without fixing with glutaraldehyde, only the monomeric form of Aβ42 was found. However, it 
cannot be excluded that glutaraldehyde itself may have an influence on the aggregation of 
Aβ42. 
 
5.1.4 Phagocytosis of Aβ42 
In Paper I and III, the effects of n-3 FAs and SPMs on microglial phagocytosis of Aβ42 were 
studied. The results showed that DHA, EPA and one of the DHA derivatives, MaR1, 
increased the phagocytosis of Aβ42, whereas neither LXA4 nor RvD1 nor PDX had an effect. 
Altogether, these results indicate that the increased phagocytosis of Aβ42 induced by DHA 
(Paper I) is mediated by its downstream product MaR1, but not by anyone of the other 
derivatives of DHA, i.e. RvD1 or PD1 (for which PDX is an analogue). This is contradictory 
to previously published results showing that also these SPMs are potent in stimulating 
phagocytosis by macrophages [124, 224, 225]. To our knowledge, the effects of SPMs on 
phagocytosis of Aβ in microglial cells have not been reported earlier. However, RvD1 was 
shown to increase the phagocytosis of fibrillar Aβ by PBMC cells from AD-patients [226]. It 
is possible that microglia and PBMCs have different ability to phagocytose Aβ, or that their 
responses to SPMs differ. Studies on the effects on phagocytosis by macrophages have used 
other objects such as zymosan or apoptotic neutrophils [225, 227, 228]. Since phagocytosis of 
different objects or molecules can be mediated by distinct mechanisms, involving different 
phagocytosis receptors, it can be speculated that the signals that stimulate Aβ phagocytosis 
are different from those stimulating phagocytosis of zymosan.  
Microglial cells express various phagocytosis receptors that can recognize Aβ and cause Aβ 
internalization. It has been suggested that phagocytosis can be divided into inflammation-
associated and non-inflammation-associated (non-phlogistic) phagocytosis. Receptors such as 
CD36, CD14 and CR3 are linked to inflammation-associated phagocytosis, while receptors 
such as triggering receptor expressed on myeloid cells (TREM2) and phophatidylserine (PS) 
receptors are linked to non-phlogistic phagocytosis [229]. Therefore, to modulate 
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phagocytosis by activating anti-inflammatory receptors and thereby increasing non-phlogistic 
phagocytosis, and at the same time reducing inflammation, is an interesting perspective, and 
is exemplified in this thesis by resolution signalling. 
Furthermore, various immune-modulatory substances that exist in the biological environment 
can modulate the phagocytosis activity. It has been reported that pro-inflammatory cytokines 
suppress the phagocytosis of fibrillar Aβ, and that this can be restored by co-incubation with 
anti-inflammatory molecules, such as anti-inflammatory cytokines and the COX inhibitor 
ibuprofen [230]. It is well documented that AD involves a chronic inflammation in the brain 
[231, 232], and hence reducing the inflammation and promoting non-phlogistic phagocytosis 
represent a potential treatment. The findings from Paper I and III indicate that n-3 FAs and 
SPMs represent such treatments.  
However, phagocytosis is not the end of the story, the fate of Aβ after internalization is also 
an important aspect to consider. We have previously shown that Aβ taken up by microglia is 
co-localized with lysosome, indicating that it is destined for degradation [233]. However, 
delivery to the lysosome does not equal degradation, as sufficient lysosome acidification and 
lysosome proteinases are required for a successful degradation [234]. 
Whether pro-resolving treatments as performed in Paper I and III are sufficient to induce the 
degradation of Aβ is a question that needs to be addressed in future studies.  
  
5.2 MODIFYING MICROGLIAL PHENOTYPE AS TREATMENT FOR DISEASE 
(PAPER I, III) 
5.2.1 Microglial phenotype  
Monitoring microglial activation has been proposed as a way to monitor the inflammation in 
AD. Mitochondrial translocator protein (TSPO) is predominantly expressed by activated 
microglia, thus representing a potential marker for neuroinflammation, and has been 
developed recently as a PET tracer [235]. However, since there are both good and bad aspects 
linked to microglial activation, monitoring activation without taking into account the different 
phenotypes may not give the whole picture of inflammation in the brain. Furthermore, in situ 
microglia exhibit a continuous spectrum of activation, and the M1 and M2 phenotypes can 
only be viewed as two extremes of activation. Even though microglia have been reported to 
be activated towards predominantly one direction in the pro- to anti-inflammatory spectrum 
in in vitro cultures, it is at present impossible to reliably assess which phenotype of activation 
microglia have in the in vivo situation, since a mixture of pro- and anti-inflammatory markers 
may be expressed [236]. Furthermore, microglial cells express an abundance of markers, 
which are adapted to their different functions in different scenarios. The tendency of us 
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researchers to force markers into categories of pro- or anti-inflammatory activation may make 
research easier, but may obscure the more complex reality. 
 
5.2.2 Immunomodulatory effects of n-3 FAs and SPMs on microglia  
In Paper I and III, we have also analysed the immunomodulatory effects of n-3 FAs (Paper 
I) and SPMs (Paper III) on Aβ42-induced changes in microglial phenotype. Both DHA and 
EPA down-regulated the pro-inflammatory M1 markers CD40 and CD86, and EPA up-
regulated the anti-inflammatory M2 marker CD206. Both RvD1 and MaR1 down-regulated 
the Aβ42-induced up-regulation of CD40 and CD11b (activated). It may be speculated that the 
anti-inflammatory effect of SPMs is stronger than that of n-3 FAs, as SPMs are downstream 
derivatives of n-3 FAs. However, no studies have directly compared the efficacy of their anti-
inflammatory actions, and adequate comparisons between Paper I and Paper III are not 
possible since different concentrations of Aβ42 were used. However, DHA, EPA and MaR1 
seemed to be most effective in promoting phagocytosis in the 10 – 100 nM range (Paper I, 
Fig. 2; Paper III, Fig. 7). In the case of the immunomodulatory effects of n-3 FAs and SPMs, 
however, the effective concentrations seemed to have a broader range, and the dose-
dependency is not as clear as that seen with regard to phagocytosis (Paper I, Fig. 3-4; Paper 
III, Fig. 6). The broad range of effective concentrations can be due to multiple pathways 
involved in mediating the anti-inflammatory action of n-3 FAs and SPMs. DHA and EPA 
have been shown bind to GPR120 with low affinity [176]. Similarly to the SPM receptors, 
GPR120 has been shown as a receptor for pro-inflammatory ligands such as saturated FAs 
[237]. In addition, PPAR-γ has been shown to be a nuclear receptor for both n-3 FAs and 
SPMs [155, 175, 238-240], with a variety of ligands such as eicosanoids [238, 241]. Whether 
these ligands counter-regulate each other, or work synergistically, is a question that should be 
addressed. 
 
5.3 HOW TO TARGET INFLAMMATION AS TREATMENT FOR AD? 
The main finding in Paper II is that Aβ-induced inflammatory responses differ from a 
conventional infectious stimulus as in that induced by bacterial LPS. Both Aβ and LPS 
induced pro-inflammatory activation of the microglia, but the factors related to resolution of 
inflammation were suppressed by Aβ and not by LPS, indicating a difference in the 
inflammation induced by these between the two causative agents. Inflammation is a common 
feature for a variety of very different diseases and may present itself differently. In the 
following two paragraphs the question regarding different types of inflammation and their 
progression to resolution will be discussed.  
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5.3.1 Different types of inflammation  
Is inflammation different dependent on the disease, and is the pathogenesis of these diseases 
affected by inflammation in different ways? In a study where the authors compared 
inflammation-related gene changes in neuroinflammatory diseases such as AD, Parkinson’s 
disease (PD), schizophrenia (SCZ) and multiple sclerosis (MS), with peripheral inflammatory 
diseases such as ulcerative colitis (UC) and inflammatory bowel disease (IBD), using 
unsupervised hierarchical clustering analysis, they found that MS had an inflammatory gene 
profile that was clustered with peripheral inflammatory diseases, but not with the other 
neuroinflammatory diseases [242]. A plausible explanation for this is that MS is an 
autoimmune disease that involves the infiltration of peripheral immune cells such as T-cells, 
whereas there is no clear evidence for infiltration of peripheral blood cells in 
neurodegenerative disorders such as AD. Together with our findings in Paper II, this 
suggests that different types of inflammation do exist, and exploring the differences between 
these common inflammatory diseases may help us to understand the etiology of the diseases, 
and to design disease-specific drugs modifying the inflammation. 
 
5.3.2 Inflammation at different stages of AD  
The question whether inflammation is a cause or the consequence of the pathology in AD is 
controversial, and little is known regarding the role of resolution in AD. To pinpoint the role 
of inflammation and resolution of inflammation in AD, we need to know how they change 
during the pathological course of the disease in comparison with normal aging.  
Aging is associated with a gradual increase in inflammation as shown by increased microglial 
activation [243, 244] and increased plasma levels of pro-inflammatory cytokines such as IL-6 
and TNF-α [245, 246]. Resolution of inflammation in normal human aging has not been 
investigated. However, in a senescence-accelerated mouse model (SAMP8), resolution of 
inflammation was suggested to be insufficient to cope with the increased levels of 
inflammation associated with aging [247]. 
AD is associated with increased inflammation compared to age-matched controls [248]. 
However, in general, longitudinal studies that monitor inflammation in the pathological 
course of AD are lacking. MCI is considered as the prodromal stages of AD, and therefore 
comparing inflammation-related changes in MCI with AD and with healthy controls can give 
some hints about changes of inflammation during the progression AD. It seems that the 
changes of inflammatory cytokines during the disease are very dynamic. At the individual 
cytokine level, there are data showing an increase, a temporary increase, unchanged or 
decreased levels [101] during the pathological course of AD, indicating the complexity of the 
inflammatory process in AD. 
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The differentially altered inflammatory cytokines during the progression of AD may play 
distinct roles at different stages of the disease. The levels of LXA4 in CSF were found to be 
lower in AD compared to both MCI and control subjects. It may be speculated that the pro-
resolution signal steadily decreases as AD-pathology progresses [101].  
As indicated in Paper II, Aβ induces inflammation but suppresses resolution. However, 
inflammatory changes have been reported to precede the plaque deposition [25, 249]. In 
addition, persons with a family history of late-onset AD have been reported to be hyper-
responsive to inflammatory stimuli [250]. The real picture is conceivably more complex, and 
more research needed before we can fully understand the role of inflammation in AD.  
 
5.3.3 Anti-inflammation as a therapy for AD  
Epidemiological studies showed an association between the intake of NSAIDs and a lower 
prevalence of AD [251]. A similar association was found for the intake of n-3 FAs [252]. 
Inspired by the epidemiological studies, several studies have been carried out to investigate 
the possibility to treat and prevent AD by NSAIDs [253] and n-3 FAs [254-256]. However, 
these studies have rendered varying results. With regard to n-3 FAs, beneficial effects have 
been found in subpopulations with very mild cognitive impairment or only in ApoE4 non-
carriers [256, 257]. Heterogeneous study populations may mask small improvements in 
cognition, and it may be that there are forms of pathology in AD that inhibit the beneficial 
effects of n-3 FAs and NSAIDs, as indicated by the results from Paper IV where 6 months n-
3 FA supplementation increased the levels of DHA, but not its down-stream product RvD1. 
Adding current knowledge on NSAIDs and n-3 FAs and analysis of common features may 
render new ideas, and the resolution of inflammation may represent a converging point.  
  
5.4 HOW TO TARGET RESOLUTION OF INFLAMMATION FOR AD?   
Resolution of inflammation represents a novel strategy that differs from treatments with anti-
inflammatory drugs, which inhibit a pathway or block the synthesis of pro-inflammatory 
mediators. Instead, stimulating pro-resolving activities represents a way to end inflammation 
in a similar fashion as under normal physiological conditions. In the following, three possible 
means to stimulate the resolution of inflammation will be discussed, i.e. treatment with 
precursors of SPMs (Paper I), direct treatment with SPMs (Paper III), and stimulation of the 
endogenous production of SPMs (Paper I and IV).   
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5.4.1 n-3 FAs (precursors of SPMs) 
Several epidemiological studies suggest that an increased intake of n-3 FAs is associated with 
reduced risk of dementia [258-260]. However, clinical trials that treat AD patients with n-3 
FAs have not been clearly successful [254, 255, 261]. As discussed above, an explanation 
could be that there are factors that prohibit beneficial effects in late-stage AD patients. A lack 
of conversion from n-3 FAs to SPMs can be one of the factors (Paper IV). This led us to 
hypothesize that SPMs represent the effective molecular components that mediate the 
beneficial effects of n-3 FAs, as observed in epidemiological studies, i.e. n-3 FAs are less 
effective if they are not converted to SPMs. A consecutive hypothesis is that this conversion 
can be inhibited in states of pathology such as found in AD. This can explain the gap between 
the epidemiological studies and the clinical trials on AD patients. In Paper IV it was found 
that although AD patients respond to n-3 FA supplementation with increased plasma levels of 
DHA and EPA (see Paper IV), this increase is not accompanied with an increase in 
important down-stream effectors - SPMs.  
 
5.4.2 SPMs  
With a normal diet, n-3 FAs can be converted from other essential FAs, and it is hypothesized 
that this conversion is disturbed in AD, which together with a decreased capacity of 
conversion to SPMs can lead to decreased levels of SPMs. Supporting this hypothesis, lower 
levels of NPD1 and LXA4 have been found in the hippocampus [125, 136], and CSF[136] of 
AD patients, indicating that increasing the levels of SPMs may represent a better choice than 
treatment with n-3 FAs. Furthermore, the levels of both LXA4 and RvD1 in CSF samples 
correlated with MMSE scores [136], suggesting an association between these SPMs and 
cognitive function. In studies on the ENT (Paper III), using an LC-MS-MS approach, we 
found that the levels of PD1 as well as MaR1 were lower in AD. Furthermore, RvD5 was 
detected in the human brain for the first time, and exhibited lower levels in AD patients as 
compared to age-matched controls. In contrast, the levels of the pro-inflammatory PGD2 were 
higher in AD. Thus, together with previous findings our data indicate a disturbance in the 
resolution of inflammation in AD, and counteracting this by stimulation of pro-resolving 
activites may be a therapeutic target for AD. 
SPMs has been shown to exert beneficial effects in various disease models (see Table 1), and 
chronic administration of AT-LXA4 has been shown to ameliorate AD pathology in the 
3xTgAD mouse model [164, 165], supporting that treatment with SPMs may be a successful 
therapeutic strategy. However, before it can be tried on AD patients, several questions need to 
be addressed.   
Safety is one of the most important aspects to consider. n-3 FAs have been shown to 
contribute to an increased risk of bleeding and hemorrhagic stroke, due to their effects on 
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platelet aggregation [262]. n-3 FA supplementation has also been associated with suppressed 
immune responses to infections [263-265]. No side effects of SPMs have been reported so far, 
but being the downstream products of n-3 FAs, this needs to be investigated. Considering that 
SPMs are relatively new subjects of research, more studies focused on safety are needed to 
rule out potential harmful effects. The administration route also needs to be considered. There 
is no direct evidence showing that SPMs can pass the BBB. However, since SPMs are small 
molecular weight lipophilic molecules, it is conceivable that they cross the BBB, similarly to 
their precursors DHA and EPA. In the OmegAD study, 6 months n-3 FA supplementation 
increased the levels of DHA, EPA and DPA in plasma (Paper IV), and in CSF [123]. 
However, the efficacy of n-3 supplementation in increasing brain levels of n-3 FAs has not 
been fully clarified.  
The choice of SPMs for use in treatments is another important question to consider, in Paper 
III we showed that SPMs have different efficacy regarding neuroprotection, anti-
inflammation and phagocytosis, even though SPMs have similar biological functions such as 
anti-inflammation and promoting phagocytosis (see introduction), the difference of action 
between different SPMs have not been reported. In addition, each SPM has different 
analogues with similar chemical structures, and the biological differences between them are 
largely unknown. Whether one SPM is more effective than another, or if a combination effect 
is stronger, need to be further investigated. 
 
5.4.3 Promoting endogenous production – class-switching  
A treatment strategy based on overcoming the potential inhibitory effect of AD pathology on 
SPM production represents an alternative approach. By stimulating the endogenous 
production and promoting class-switching, the levels of SPMs may be increased. In addition 
to α7nAchR activation, discussed in the Introduction, non-selective COX-inhibitors such as 
aspirin, PPAR-γ agonists, and anti-inflammatory cytokines have been indicated in the 
literature to be involved in class-switching. 
Aspirin is a well-known NSAID, widely used for treatment of inflammation. Low doses of 
aspirin are prescribed for the prevention of cardiovascular events. The mechanism of action 
for aspirin is through acetylation of COX-1 and thereby affecting its catalytic activity and 
inhibiting the synthesis of PGs and thromboxanes (TXs) [200]. In addition, aspirin has been 
found to stimulate resolution of inflammation by acetylating COX-2 [202], which gives rise 
to the production of aspirin-triggered form of SPMs. Due to side effects of aspirin, such as 
gastrointestinal (GI) irritation [266], the development of more specific modulators of COXs 
could help promoting the production of SPMs without causing side effects.  
The PPAR-γ agonist rosiglitazone has been shown to increase the production of LXA4 [155]. 
However, due to its multi-ligand binding capacity, e.g. in glucose-lowering, used in treatment 
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of diabetes [267], the mechanism for its effect on LXA4 production needs to be investigated 
in order to target this pathway. Anti-inflammatory cytokines such as IL-13 have been shown 
to increase the expression of 15-LOX-1 [268], and may therefore help stimulating the 
production of SPMs, although the balance between the beneficial and detrimental effects of 
15-LOX-1 must be taken into account. Lastly, phosphorylation of 5-LOX at Serine 523 has 
been shown to increase the production of LXA4 and to reduce the production of LTB4 [182, 
183], indicating another possible target for stimulating the endogenous resolution of 
inflammation. 
    
5.5 INDIVIDUALIZED THERAPY FOR AD BASED ON GENOTYPE AND 
DISEASE STAGE   
In Paper IV we investigate the effects of n-3 FA supplementation on the release of SPMs in 
relation to the presence of an ApoE4 genotype in AD patients. Patients from the OmegAD 
study were selected according to the ApoE genotype. With the hypothesis that a possible 
influence of the E4 allele would be larger in ApoE4 double carriers, the study was based on 
these and ApoE4 non-carriers.  In non-carriers, but not in ApoE4 carriers, the proportion of 
patients with unchanged/improved cognition was higher in patients with n-3 FA 
supplementation compared to placebo-treated patients. Thus, ApoE4 non-carriers may benefit 
more from the n-3 FA supplementation compared to the ApoE4 carriers, consistent with 
previous reports [257, 269, 270]. ApoE4 affects lipid metabolism in many different ways 
including FA processing to their down-stream products, increased lipid peroxidation, etc. Our 
data seem to support that treatment with the end products, SPMs, would be preferable over n-
3 FAs in the case of ApoE4 carriers. 
In a wider perspective, i.e. in addition to treating patients according to their genetic 
background, treatments should be designed to suit other individual pathological changes that 
may prohibit beneficial effects, as indicated from findings in Paper IV and discussed above. 
If AD pathology inhibits the conversion of n-3 FAs, patients with advanced stage of 
pathology may benefit from SPMs. Additional examples are from the Alzheimer’s Disease 
Anti-Inflammatory Prevention Trial (ADAPT), a large randomized clinical trial (2388 
patients were included) started in 2001 and designed to test the ability of the NSAIDs 
naproxen and celecoxib to delay or prevent the onset of AD and age-related cognitive decline 
[271]. The trial was designed to run for 5-7 years, but was prematurely terminated due to 
safety concerns. However, the patients were followed after the suspension of the trial. The 
primary outcome was negative [109], but re-analysis of the data from the pre-clinical group 
of patients according to their cognitive performance [272], showed that the fast-decliners 
(patients who have the strongest risk of developing AD) had beneficial effects from the non-
selective COX inhibitor naproxen, while slow-decliners (patients who have relatively lower 
risk of developing AD) had beneficial effects from the selective COX-2 inhibitor celecoxib, 
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indicating that patients with different cognitive characteristics, and at different stages of 
disease pathology, may respond to different types of NSAIDs. 
 
6 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
6.1 CONCLUDING REMARKS  
The main aim of this thesis is to investigate stimulation of resolution of inflammation as a 
therapeutic strategy for AD. We have utilized cellular models (Paper I-III), and clinical 
materials from AD patients (Paper III, IV) to address this hypothesis. Resolution signalling 
was stimulated by increasing the levels of resolution mediators, including the n-3 FAs DHA 
and EPA (precursors of SPMs), or by direct addition of SPMs. Besides treatment studies, 
Paper II characterizes the effects of different inflammatory stimuli on resolving pathways in 
microglia, comparing AD-related pathology with an infectious stimulus.  
The key findings of this thesis are summarized as follows: 
• Aβ42 induced pro-inflammatory activation and suppressed resolution in microglia.   
• Levels of MaR1, PD1, and RvD5 were lower in ENT of AD patients as compared to 
age-matched controls. 
DHA, EPA and SPMs are beneficial for AD as: 
• DHA, EPA and one of the DHA derivatives MaR1 increased the phagocytosis of 
Aβ42.  
• DHA and EPA down-regulated the pro-inflammatory markers CD40 and CD86; EPA 
up-regulated the anti-inflammatory marker CD206. 
• RvD1 and MaR1 down-regulated Aβ42-induced up-regulation of CD40 and the 
activated form of CD11b. 
• LXA4, MaR1 and RvD1 were neuroprotective against STS-induced apoptosis.  
• n-3 FA supplementation in AD patients did not increase the downstream pro-
resolving product RvD1.  
• n-3 FA supplementation reduced plasma LXA4 levels in ApoE4 double carriers, but 
not in non-carriers, which showed an increased RvD1/LTB4 ratio upon n-3 FA 
supplementation.  
To conclude, stimulating resolution of inflammation is beneficial by increasing removal of 
Aβ via phagocytosis, counter-regulating Aβ-induced pro-inflammatory microglial activation, 
and neuronal cell death. However, factors affecting resolution such as ApoE4 genotype and 
AD-related pathology need to be taken into consideration when translating the results from 
cellular studies to the clinical situation.   
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6.2 FUTURE PERSPECTIVES  
Promoting resolution of inflammation represents a novel strategy for treatment of 
inflammatory disorders. SPMs have been shown to be beneficial in various inflammatory 
cellular and animal disease models, and results from this thesis further strengthen the idea 
that stimulating resolution of inflammation towards a return of homeostasis can be a 
therapeutic target for AD. However, there is a long way to go, and we need to better 
understand the mechanisms before it can be successfully translated to the clinic: 
• Resolution of inflammation include two aspects: anti-inflammation and repair. The 
repair mechanisms are less explored. In the case of diseases with a chronic 
inflammation, such as AD, in which the tissue has already been damaged, it is 
important to investigate whether stimulating pro-resolving activties can initiate repair 
and neuronal regeneration. 
• Promoting endogenous production of SPMs, i.e. by increasing class-switching 
mechanisms is of great interest since the stability of SPMs in the brain is not fully 
known. Modulators of COXs and LOXs, as well as PPAR-γ agonists, are of potential 
interest. 
• SPMs are produced during physiological conditions, but do they have functions 
separate from their role in resolving inflammation? 
• SPMs are end products in the metabolic pathways of COXs and LOXs from PUFAs, 
and there are many intermediates in these pathways. The functions of these molecules 
are largely unknown, and need further investigation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
7 ACKNOWLEDGEMENTS 
The moment when I realized my studies were close to finish I had a feeling that I would like to 
continue. The PhD journey has been a great experience to me for being exposed to the scientific 
world, and for having chance to meet people that I would like to thank here:   
Professor Marianne Schultzberg, my main supervisor, for accepting me as a PhD student and 
guiding me all the way through my PhD journey, for your great support whenever needed both 
scientifically and emotionally, for your encouragement and understanding when I thought there was a 
problem, for being very patient and letting me learn things in my own way, and for the freedom that 
you gave me to explore the scientific questions, for all the work you did for setting up collaborations 
that made our projects go further, and for the good atmosphere that you create in our group.  
Dr. Erik Hjorth, my co-supervisor, for supervising me, a very naïve scientist, starting from very basic 
things such as how to culture cells, plan experiments and statistics, etc. I feel lucky to be your student 
and I think I have learnt a lot from you, including to come to the office early in the morning and to go 
to the gym. Thank you for always being available whenever needed, and for being very 
knowledgeable, which always makes me feel inspired after our discussions. 
Professor Maria Eriksdotter, my co-supervisor, thank you for accepting me as your student, for 
always being encouraging and for all your work you did as the head of our department. 
Professor Jiachun Feng, my supervisor and mentor in China, for encouraging me to go abroad for my 
PhD studies, for your understanding and support during the past years, for your expertise in the 
clinical work, which I need to learn a lot in the future.  
Associate Professor Jie Zhu, for introducing me to Karolinska Institutet and being supportive all these 
years.  
All our group members: Heela Sarlus, for your warm and beautiful heart under your beautiful face. 
Xiuzhe Wang, for being helpful all these years, for the collaboration of our projects, for your calm 
personality and wise advices. Veronica Cortés-Toro, for your hard work and rigorous research 
attitude. Mircea Oprica, for being humorous and creating a relaxed atmosphere during the lab-
meetings. Ann-Charlotte Granholm, for your positive energy and encouragement. Lisa Schröder, 
for your contributions to our paper and for the weekends together. Stefen Spulber, Catharina 
Lindberg and Åsa Forslin-Aronsson, for the outside lab activities and Christmas tables together.  
All the co-authors in my papers: Inger Vedin, Jan Palmblad, Tommy Cederholm, Yvonne 
Freund-Levi, Gerd Faxen-Irving, Lars-Olof Wahlund and Hans Basun from the OmegAD study 
group, for providing materials for the projects and contribution to the papers. Romain A. Colas and 
Charles N. Serhan, Harvard University, for the lipidomic analyses of human samples and valuable 
advice for our joint papers.  
  47 
All the colleagues and friends in the Division of Neurodegeneration: Erik Sundström for information 
during division meetings and journal clubs. Ning Xu, for your great support during past years. 
Elisabeth Åkesson, Per Henrik Vincent, Lena Holmberg and Eva-Britt Samuelsson, Mahmod 
Panahi, Dang Wang and Bo Zhang for creating a nice atmosphere in the lab. Special thanks to 
Maria Roos for all the information and document work.   
All senior researchers in NVS: Åke Seiger, for organizing the Kandel seminars. Homira Behbahani 
and Taher Darreh-Shori for the PhD seminars. Helena Karlström, Susanne Frykman, Elisabeth 
Åkesson, Lars Tjernberg, Lars-Olof Wahlund, Agneta Nordberg, Maria Ankarcrona, Abdul H. 
Mohammed, Dag Aarsland, Jan Johansson, Caroline Graff, Erikur Benedikz, Eric Westman 
and Ronnie Folkesson for a nice working environment and all the activities within the department.  
The Swedish Brain Power organization: especially Bengt Winblad, for the research grants you 
brought in, your enthusiasm for work and the SBP workshop, and Gunilla Johansson, for your 
administrative and organization work.  
All my dear colleagues and friends at department of NVS: Xiaozhen Li, for your wise advice, 
Ruiqing Ni, for exercising together, Qiupin Jia, for shopping together. Zhi Tang, Hongliang Zhang, 
Jia Liu, Xiangyu Zheng, Geifei Chen, Hong Yu, Xu Wang，Chi Ma and Siqin Wu, for the 
celebration of Chinese New Years together. Alina Codita for helping me with the cover of the thesis, 
Azadeh Karami, for all the pictures you took. Daniela Enache, for your kind support. Kevin Grimes 
and Seyed-Mohammad Fereshtehnejad for philosophy discussions together, Anna Sandebring, 
Gabriella Spulber, Erika Bereczki, Olga Voevodskaya, Silvia Maioli, Muhammad Al Mustafa 
Ismail, Annelie Pamrén, Elena Rodriguez-Vieitez, Bernadette Schreiner, Swetha 
Vijayaraghavan, Soheil Damangir, Farshad Falahati, Seyed Mohammad Fereshtehnejad, 
Daniel Padilla Ferreira, Carlos Aguilar, Nuninho Leal, Hue-Hsin Chen, Walid Tajeddinn, 
Torbjörn Persson, Médoune Sarr, Axel Leppert, Oihan Basabe Burgos, Nina Kronqvist, 
Kostantinos Chiotis, Antoine Leuzy, Jolanta Lundgren, Erica Lana, Lisa Dolfe, Laetitia 
Lemoine, Pavla Cermakova, Annette Karlsson, Annette Eidehall and Maggie Lukasiewicz, for 
making the NVS environment very friendly.  
All my friends in Stockholm that I didn’t mention above: Jing Lyu, for your company and support, I 
wish you good luck with your future. Yan Li, for your warm heart and help. Yang Ruan, for the time 
we spent together. Lisa Gan, for all your help and for sharing your stories.  Shaohua Xu & Lu 
Zhang, I am so sorry that I could not attend your wedding, I think you two make a nice couple and 
wish you all the best for your future. Shouting Zhang for your encouragement. Xingmei Zhang, for 
always being positive. Qingda Meng, Zhenjiang Liu, Huijie Xiao, Jia Sun, Meng Li, Yuan Zhang, 
Xintong Jiang and Yali Miao, for the nice memories that you gave.  
My dear mother and father, for your endless love and support. My sisters and my little brother, for 
your love and support, for the lovely memories that you gave, I hope we will have more chances to 
 48 
meet in the future. 我亲爱的爸爸妈妈, 感谢你们的无尽的爱与支持。我兄弟姐妹， 感谢你们关
心和支持，希望我们以后有更多的时间在一起。 
My dear husband and my son, thank you for being part of my life, for your great love and support. 我
亲爱的老公和儿子， 很遗憾和你们分开了这么长时间， 希望以后的日子我们都能快快乐乐
的在一起。 
My dear mother-in-law, thank you for all your love and support, for your warm heart and being 
positive whatever life gives us. 我亲爱的岳母， 非常感谢你对家和的照顾，让我专心的完成我
的学业，我们以后会有更多的时间在一起！ 
 
 
  49 
8 REFERENCES 
[1] Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR (1995) An English translation of 
Alzheimer's 1907 paper, "Uber eine eigenartige Erkankung der Hirnrinde". Clin Anat 8, 429-431. 
[2] Hardy J (2006) A hundred years of Alzheimer's disease research. Neuron 52, 3-13. 
[3] Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP (2013) The global prevalence of 
dementia: a systematic review and metaanalysis. Alzheimers Dement 9, 63-75 e62. 
[4] Wimo A, Jonsson L, Bond J, Prince M, Winblad B, Alzheimer Disease I (2013) The worldwide 
economic impact of dementia 2010. Alzheimers Dement 9, 1-11 e13. 
[5] Hebert LE, Weuve J, Scherr PA, Evans DA (2013) Alzheimer disease in the United States (2010-
2050) estimated using the 2010 census. Neurology 80, 1778-1783. 
[6] Schneider JA, Arvanitakis Z, Bang W, Bennett DA (2007) Mixed brain pathologies account for most 
dementia cases in community-dwelling older persons. Neurology 69, 2197-2204. 
[7] Bird TD (1993) Early-Onset Familial Alzheimer Disease In GeneReviews(R), Pagon RA, Adam MP, 
Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, eds., Seattle (WA). 
[8] Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and 
AD pathology. Neurobiol Aging 25, 641-650. 
[9] Fratiglioni L, Ahlbom A, Viitanen M, Winblad B (1993) Risk factors for late-onset Alzheimer's 
disease: a population-based, case-control study. Ann Neurol 33, 258-266. 
[10] Rusanen M, Kivipelto M, Quesenberry CP, Jr., Zhou J, Whitmer RA (2011) Heavy smoking in 
midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 171, 333-
339. 
[11] Pendlebury ST, Rothwell PM (2009) Prevalence, incidence, and factors associated with pre-stroke 
and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 8, 1006-1018. 
[12] Xu WL, Atti AR, Gatz M, Pedersen NL, Johansson B, Fratiglioni L (2011) Midlife overweight and 
obesity increase late-life dementia risk: a population-based twin study. Neurology 76, 1568-1574. 
[13] Yaffe K, Hoang TD, Byers AL, Barnes DE, Friedl KE (2014) Lifestyle and health-related risk 
factors and risk of cognitive aging among older veterans. Alzheimers Dement 10, S111-121. 
[14] Helzner EP, Scarmeas N, Cosentino S, Tang MX, Schupf N, Stern Y (2008) Survival in Alzheimer 
disease: a multiethnic, population-based study of incident cases. Neurology 71, 1489-1495. 
[15] Xie J, Brayne C, Matthews FE, Medical Research Council Cognitive F, Ageing Study c (2008) 
Survival times in people with dementia: analysis from population based cohort study with 14 year 
follow-up. BMJ 336, 258-262. 
[16] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis 
of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of 
Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-
944. 
[17] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, 
Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, 
Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer's disease: 
recommendations from the National Institute on Aging-Alzheimer's Association workgroups on 
diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 263-269. 
[18] Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, 
Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild 
cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on 
Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement 7, 270-279. 
[19] Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, dimebon i 
(2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in 
patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled 
study. Lancet 372, 207-215. 
[20] Imbimbo BP, Solfrizzi V, Panza F (2010) Are NSAIDs useful to treat Alzheimer's disease or mild 
cognitive impairment? Front Aging Neurosci 2. , PMID: 20725517. 
[21] Mullane K, Williams M (2013) Alzheimer's therapeutics: continued clinical failures question the 
validity of the amyloid hypothesis-but what lies beyond? Biochem Pharmacol 85, 289-305. 
[22] Burke V, Beilin LJ, Cutt HE, Mansour J, Williams A, Mori TA (2007) A lifestyle program for 
treated hypertensives improved health-related behaviors and cardiovascular risk factors, a 
randomized controlled trial. J Clin Epidemiol 60, 133-141. 
[23] McGeer PL, Itagaki S, Tago H, McGeer EG (1987) Reactive microglia in patients with senile 
dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. 
Neurosci Lett 79, 195-200. 
[24] McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR 
in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291. 
 50 
[25] Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) 
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer 
disease. Proc Natl Acad Sci U S A 86, 7611-7615. 
[26] Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A, Nishimura T 
(1994) Brain interleukin-1β in Alzheimer's disease and vascular dementia. Methods Find Exp Clin 
Pharmacol 16, 141-151. 
[27] Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, 
Irving N, James L, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein 
gene with familial Alzheimer's disease. Nature 349, 704-706. 
[28] Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, 
Holman K, Tsuda T, Mar L, Foncin JF, Bruni AC, Montesi MP, Sorbi S, Rainero I, Pinessi L, Nee L, 
Chumakov I, Pollen D, Brookes A, Sanseau P, Polinsky RJ, Wasco W, Da Silva HA, Haines JL, 
Perkicak-Vance MA, Tanzi RE, Roses AD, Fraser PE, Rommens JM, St George-Hyslop PH (1995) 
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 
375, 754-760. 
[29] Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, 
Tsuda T, et al. (1995) Familial Alzheimer's disease in kindreds with missense mutations in a gene on 
chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778. 
[30] Guerreiro R, Hardy J (2014) Genetics of Alzheimer's disease. Neurotherapeutics 11, 732-737. 
[31] Chouraki V, Seshadri S (2014) Genetics of Alzheimer's disease. Adv Genet 87, 245-294. 
[32] Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Aβ peptide induces tau 
phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115, 
201-211. 
[33] Busciglio J, Lorenzo A, Yeh J, Yankner BA (1995) β-amyloid fibrils induce tau phosphorylation and 
loss of microtubule binding. Neuron 14, 879-888. 
[34] Franco R, Cedazo-Minguez A (2014) Successful therapies for Alzheimer's disease: why so many in 
animal models and none in humans? Front Pharmacol 5, 146. 
[35] Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni G (1995) Reciprocal control of 
inflammatory cytokines, IL-1 and IL-6, and Aβ production in cultures. Neurosci Lett 188, 70-74. 
[36] Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB (2004) Interleukin-6 induces 
Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 
295, 245-257. 
[37] Golde TE, Estus S, Younkin LH, Selkoe DJ, Younkin SG (1992) Processing of the amyloid protein 
precursor to potentially amyloidogenic derivatives. Science 255, 728-730. 
[38] Hardy J (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem 
110, 1129-1134. 
[39] Wicklund L, Leao RN, Stromberg AM, Mousavi M, Hovatta O, Nordberg A, Marutle A (2010) Aβ42 
oligomers impair function of human embryonic stem cell-derived forebrain cholinergic neurons. 
PLoS ONE 5, e15600. 
[40] Combs CK, Karlo JC, Kao SC, Landreth GE (2001) β-amyloid stimulation of microglia and 
monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal 
apoptosis. J Neurosci 21, 1179-1188. 
[41] Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of 
amyloid-β protein. J Alzheimers Dis 3, 75-80. 
[42] Goto Y, Yagi H, Yamaguchi K, Chatani E, Ban T (2008) Structure, formation and propagation of 
amyloid fibrils. Curr Pharm Des 14, 3205-3218. 
[43] Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in 
Alzheimer disease. Cold Spring Harb Perspect Med 1, a006189. 
[44] Furst AJ, Rabinovici GD, Rostomian AH, Steed T, Alkalay A, Racine C, Miller BL, Jagust WJ 
(2012) Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging 
33, 215-225. 
[45] Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain 
amyloid-β oligomers in ageing and Alzheimer's disease. Brain 136, 1383-1398. 
[46] Kayed R, Lasagna-Reeves CA (2013) Molecular mechanisms of amyloid oligomers toxicity. J 
Alzheimers Dis 33 Suppl 1, S67-78. 
[47] Hersh LB, Rodgers DW (2008) Neprilysin and amyloid β peptide degradation. Curr Alzheimer Res 
5, 225-231. 
[48] Saido T, Leissring MA (2012) Proteolytic degradation of amyloid-β protein. Cold Spring Harb 
Perspect Med 2, a006379. 
[49] Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-β peptide in 
Alzheimer's disease: review and hypothesis. Neurobiol Aging 27, 190-198. 
[50] Yan P, Hu X, Song H, Yin K, Bateman RJ, Cirrito JR, Xiao Q, Hsu FF, Turk JW, Xu J, Hsu CY, 
Holtzman DM, Lee JM (2006) Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and 
compact plaques in situ. J Biol Chem 281, 24566-24574. 
  51 
[51] Donahue JE, Flaherty SL, Johanson CE, Duncan JA, 3rd, Silverberg GD, Miller MC, Tavares R, 
Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG (2006) RAGE, LRP-1, and amyloid-β protein in 
Alzheimer's disease. Acta Neuropathol 112, 405-415. 
[52] Vogelgesang S, Jedlitschky G, Brenn A, Walker LC (2011) The role of the ATP-binding cassette 
transporter P-glycoprotein in the transport of β-amyloid across the blood-brain barrier. Curr Pharm 
Des 17, 2778-2786. 
[53] Zlokovic BV (2004) Clearing amyloid through the blood-brain barrier. J Neurochem 89, 807-811. 
[54] Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin 
C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek 
B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B (2003) RAGE mediates amyloid-β peptide 
transport across the blood-brain barrier and accumulation in brain. Nat Med 9, 907-913. 
[55] Karran E, Hardy J (2014) A critique of the drug discovery and phase 3 clinical programs targeting 
the amyloid hypothesis for Alzheimer disease. Ann Neurol 76, 185-205. 
[56] Iqbal K, Liu F, Gong CX, Grundke-Iqbal I (2010) Tau in Alzheimer disease and related tauopathies. 
Curr Alzheimer Res 7, 656-664. 
[57] Alonso AC, Li B, Grundke-Iqbal I, Iqbal K (2008) Mechanism of tau-induced neurodegeneration in 
Alzheimer disease and related tauopathies. Curr Alzheimer Res 5, 375-384. 
[58] Sigurdsson EM (2014) Tau immunotherapy and imaging. Neurodegener Dis 13, 103-106. 
[59] Gong CX, Iqbal K (2008) Hyperphosphorylation of microtubule-associated protein tau: a promising 
therapeutic target for Alzheimer disease. Curr Med Chem 15, 2321-2328. 
[60] Scott A, Khan KM, Cook JL, Duronio V (2004) What is "inflammation"? Are we ready to move 
beyond Celsus? Br J Sports Med 38, 248-249. 
[61] Tracy RP (2006) The five cardinal signs of inflammation: Calor, Dolor, Rubor, Tumor ... and 
Penuria (Apologies to Aulus Cornelius Celsus, De medicina, c. A.D. 25). J Gerontol A Biol Sci Med 
Sci 61, 1051-1052. 
[62] Noble M (2004) The possible role of myelin destruction as a precipitating event in Alzheimer's 
disease. Neurobiol Aging 25, 25-31. 
[63] Lyros E, Bakogiannis C, Liu Y, Fassbender K (2014) Molecular links between endothelial 
dysfunction and neurodegeneration in Alzheimer's disease. Curr Alzheimer Res 11, 18-26. 
[64] Alliot F, Godin I, Pessac B (1999) Microglia derive from progenitors, originating from the yolk sac, 
and which proliferate in the brain. Brain Res Dev Brain Res 117, 145-152. 
[65] Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, Mehler MF, Conway SJ, Ng LG, 
Stanley ER, Samokhvalov IM, Merad M (2010) Fate mapping analysis reveals that adult microglia 
derive from primitive macrophages. Science 330, 841-845. 
[66] Ajami B, Bennett JL, Krieger C, Tetzlaff W, Rossi FM (2007) Local self-renewal can sustain CNS 
microglia maintenance and function throughout adult life. Nat Neurosci 10, 1538-1543. 
[67] Elmore MR, Najafi AR, Koike MA, Dagher NN, Spangenberg EE, Rice RA, Kitazawa M, Matusow 
B, Nguyen H, West BL, Green KN (2014) Colony-stimulating factor 1 receptor signaling is 
necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. Neuron 
82, 380-397. 
[68] Ladeby R, Wirenfeldt M, Garcia-Ovejero D, Fenger C, Dissing-Olesen L, Dalmau I, Finsen B (2005) 
Microglial cell population dynamics in the injured adult central nervous system. Brain Res Brain Res 
Rev 48, 196-206. 
[69] Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P, Giustetto M, Ferreira TA, 
Guiducci E, Dumas L, Ragozzino D, Gross CT (2011) Synaptic pruning by microglia is necessary 
for normal brain development. Science 333, 1456-1458. 
[70] Hjorth E, Frenkel D, Weiner H, Schultzberg M (2010) Effects of immunomodulatory substances on 
phagocytosis of Aβ42 by human microglia. Int J Alzheimers Dis 10.4061/2010/798424. 
[71] Durafourt BA, Moore CS, Zammit DA, Johnson TA, Zaguia F, Guiot MC, Bar-Or A, Antel JP 
(2012) Comparison of polarization properties of human adult microglia and blood-derived 
macrophages. Glia 60, 717-727. 
[72] Perry VH, Teeling J (2013) Microglia and macrophages of the central nervous system: the 
contribution of microglia priming and systemic inflammation to chronic neurodegeneration. Semin 
Immunopathol 35, 601-612. 
[73] Gomez-Nicola D, Perry VH (2015) Microglial Dynamics and Role in the Healthy and Diseased 
Brain: A Paradigm of Functional Plasticity. Neuroscientist 21, 169-184. 
[74] Eikelenboom P, Stam FC (1982) Immunoglobulins and complement factors in senile plaques. An 
immunoperoxidase study. Acta Neuropathol 57, 239-242. 
[75] Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Campanella GK, Luster AD, Silverstein 
SC, El-Khoury JB (2002) CD36, a class B scavenger receptor, is expressed on microglia in 
Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-
amyloid fibrils. Am J Pathol 160, 101-112. 
[76] Strohmeyer R, Ramirez M, Cole GJ, Mueller K, Rogers J (2002) Association of factor H of the 
alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease 
brain. J Neuroimmunol 131, 135-146. 
 52 
[77] Zhang D, Hu X, Qian L, Chen SH, Zhou H, Wilson B, Miller DS, Hong JS (2011) Microglial MAC1 
receptor and PI3K are essential in mediating β-amyloid peptide-induced microglial activation and 
subsequent neurotoxicity. J Neuroinflammation 8, 3. 
[78] Griciuc A, Serrano-Pozo A, Parrado AR, Lesinski AN, Asselin CN, Mullin K, Hooli B, Choi SH, 
Hyman BT, Tanzi RE (2013) Alzheimer's disease risk gene CD33 inhibits microglial uptake of 
amyloid-β. Neuron 78, 631-643. 
[79] Bradshaw EM, Chibnik LB, Keenan BT, Ottoboni L, Raj T, Tang A, Rosenkrantz LL, Imboywa S, 
Lee M, Von Korff A, Alzheimer Disease Neuroimaging I, Morris MC, Evans DA, Johnson K, 
Sperling RA, Schneider JA, Bennett DA, De Jager PL (2013) CD33 Alzheimer's disease locus: 
altered monocyte function and amyloid biology. Nat Neurosci 16, 848-850. 
[80] Takuma K, Fang F, Zhang W, Yan S, Fukuzaki E, Du H, Sosunov A, McKhann G, Funatsu Y, 
Nakamichi N, Nagai T, Mizoguchi H, Ibi D, Hori O, Ogawa S, Stern DM, Yamada K, Yan SS 
(2009) RAGE-mediated signaling contributes to intraneuronal transport of amyloid-β and neuronal 
dysfunction. Proc Natl Acad Sci U S A 106, 20021-20026. 
[81] Takano T, Fiore S, Maddox JF, Brady HR, Petasis NA, Serhan CN (1997) Aspirin-triggered 15-epi-
lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence 
for anti-inflammatory receptors. J Exp Med 185, 1693-1704. 
[82] Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ (2010) Astrocytes in Alzheimer's 
disease. Neurotherapeutics 7, 399-412. 
[83] Thangavel R, Stolmeier D, Yang X, Anantharam P, Zaheer A (2012) Expression of glia maturation 
factor in neuropathological lesions of Alzheimer's disease. Neuropathol Appl Neurobiol 38, 572-581. 
[84] Pike CJ, Cummings BJ, Cotman CW (1995) Early association of reactive astrocytes with senile 
plaques in Alzheimer's disease. Exp Neurol 132, 172-179. 
[85] Shao Y, Gearing M, Mirra SS (1997) Astrocyte-apolipoprotein E associations in senile plaques in 
Alzheimer disease and vascular lesions: a regional immunohistochemical study. J Neuropathol Exp 
Neurol 56, 376-381. 
[86] DeWitt DA, Perry G, Cohen M, Doller C, Silver J (1998) Astrocytes regulate microglial 
phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 149, 329-340. 
[87] Bartfai T, Schultzberg M (1993) Cytokines in neuronal cell types. Neurochem Int 22, 435-444. 
[88] Ek M, Kurosawa M, Lundeberg T, Ericsson A (1998) Activation of vagal afferents after intravenous 
injection of interleukin-1β: role of endogenous prostaglandins. J Neurosci 18, 9471-9479. 
[89] Patterson PH, Nawa H (1993) Neuronal differentiation factors/cytokines and synaptic plasticity. Cell 
72 Suppl, 123-137. 
[90] Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR (2003) 
Cytokine-induced sickness behavior. Brain Behav Immun 17 Suppl 1, S112-118. 
[91] Holmannova D, Kolackova M, Kondelkova K, Kunes P, Krejsek J, Andrys C (2012) 
CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; 
Part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec Kralove) 55, 12-17. 
[92] Walker DG, Dalsing-Hernandez JE, Campbell NA, Lue LF (2009) Decreased expression of CD200 
and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. 
Exp Neurol 215, 5-19. 
[93] Togo T, Akiyama H, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K (2000) Expression of CD40 in 
the brain of Alzheimer's disease and other neurological diseases. Brain Res 885, 117-121. 
[94] Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, Mattson MP, Flavell RA, Mullan M (1999) 
Microglial activation resulting from CD40-CD40L interaction after β-amyloid stimulation. Science 
286, 2352-2355. 
[95] Trinchieri G (2004) Cytokines and cytokine receptors. Immunol Rev 202, 5-7. 
[96] Schneider H, Pitossi F, Balschun D, Wagner A, del Rey A, Besedovsky HO (1998) A 
neuromodulatory role of interleukin-1β in the hippocampus. Proc Natl Acad Sci U S A 95, 7778-
7783. 
[97] Avital A, Goshen I, Kamsler A, Segal M, Iverfeldt K, Richter-Levin G, Yirmiya R (2003) Impaired 
interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural 
plasticity. Hippocampus 13, 826-834. 
[98] Spulber S, Mateos L, Oprica M, Cedazo-Minguez A, Bartfai T, Winblad B, Schultzberg M (2009) 
Impaired long term memory consolidation in transgenic mice overexpressing the human soluble form 
of IL-1ra in the brain. J Neuroimmunol 208, 46-53. 
[99] Bellinger FP, Madamba S, Siggins GR (1993) Interleukin 1β inhibits synaptic strength and long-term 
potentiation in the rat CA1 hippocampus. Brain Res 628, 227-234. 
[100] Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW, Maier SF (2009) Time 
course of hippocampal IL-1β and memory consolidation impairments in aging rats following 
peripheral infection. Brain Behav Immun 23, 46-54. 
[101] Brosseron F, Krauthausen M, Kummer M, Heneka MT (2014) Body fluid cytokine levels in mild 
cognitive impairment and Alzheimer's disease: a comparative overview. Mol Neurobiol 50, 534-544. 
[102] Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB 
(2001) In-vivo measurement of activated microglia in dementia. Lancet 358, 461-467. 
  53 
[103] Tosto G, Reitz C (2013) Genome-wide association studies in Alzheimer's disease: a review. Curr 
Neurol Neurosci Rep 13, 381. 
[104] Meda L, Cassatella MA, Szendrei GI, Otvos L, Jr., Baron P, Villalba M, Ferrari D, Rossi F (1995) 
Activation of microglial cells by β-amyloid protein and interferon-γ. Nature 374, 647-650. 
[105] Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ (1998) Amyloid-β peptide activates 
cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 
785, 195-206. 
[106] Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P, Grubeck-
Loebenstein B (2000) Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis 
factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol Dis 7, 682-689. 
[107] Dash PK, Moore AN (1995) Enhanced processing of APP induced by IL-1β can be reduced by 
indomethacin and nordihydroguaiaretic acid. Biochem Biophys Res Commun 208, 542-548. 
[108] McGeer PL, McGeer E, Rogers J, Sibley J (1990) Anti-inflammatory drugs and Alzheimer disease. 
Lancet 335, 1037. 
[109] Group AR, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M 
(2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled 
trial. Neurology 68, 1800-1808. 
[110] Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC, 
Rofecoxib Protocol 091 Study G (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, 
randomized, blinded, controlled study. Neurology 62, 66-71. 
[111] Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N (1999) A double-blind, placebo-controlled 
trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53, 197-201. 
[112] O'Bryant Sea (2014) A proinflammatory endophenotype predicts treatment response in a multicenter 
trial of NSAIDs in AD. Alzheimer's & Dementia 10, P273 - P274. 
[113] Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T, Spener F, van Meer G, 
Wakelam MJ, Dennis EA (2009) Update of the LIPID MAPS comprehensive classification system 
for lipids. J Lipid Res 50 Suppl, S9-14. 
[114] Andersen OS, Koeppe RE, 2nd (2007) Bilayer thickness and membrane protein function: an 
energetic perspective. Annu Rev Biophys Biomol Struct 36, 107-130. 
[115] Spite M (2013) Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in 
health and disease. Proc Nutr Soc 72, 441-450. 
[116] Shimizu T (2009) Lipid mediators in health and disease: enzymes and receptors as therapeutic targets 
for the regulation of immunity and inflammation. Annu Rev Pharmacol Toxicol 49, 123-150. 
[117] Farooqui AA (2011) Lipid mediators and their metabolism in the brain, Springer, New York. 
[118] Robinson PG (1982) Common names and abbreviated formulae for fatty acids. J Lipid Res 23, 1251-
1253. 
[119] Whitney E (2014) Understanding nutrition, Cengage Learning, San Francisco, CA. 
[120] Hansen AE, Burr GO (1946) Essential fatty acids and human nutrition. J Am Med Assoc 132, 855-
859. 
[121] Holman RT (1960) Essential fatty acids in nutrition and metabolism. Arch Intern Med 105, 33-38. 
[122] Williams CM, Burdge G (2006) Long-chain n-3 PUFA: plant v. marine sources. Proc Nutr Soc 65, 
42-50. 
[123] Freund Levi Y, Vedin I, Cederholm T, Basun H, Faxen Irving G, Eriksdotter M, Hjorth E, 
Schultzberg M, Vessby B, Wahlund LO, Salem N, Jr., Palmblad J (2014) Transfer of omega-3 fatty 
acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich 
omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study. J Intern 
Med 275, 428-436. 
[124] Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-
101. 
[125] Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG 
(2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and 
Alzheimer disease. J Clin Invest 115, 2774-2783. 
[126] Kang J, Rivest S (2012) Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for 
liver X receptors. Endocr Rev 33, 715-746. 
[127] Kanekiyo T, Xu H, Bu G (2014) ApoE and Aβ in Alzheimer's disease: accidental encounters or 
partners? Neuron 81, 740-754. 
[128] Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity 
in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque 
amyloid in Creutzfeldt-Jakob disease. Brain Res 541, 163-166. 
[129] Pirttila T, Soininen H, Heinonen O, Lehtimaki T, Bogdanovic N, Paljarvi L, Kosunen O, Winblad B, 
Riekkinen P, Sr., Wisniewski HM, Mehta PD (1996) Apolipoprotein E (apoE) levels in brains from 
Alzheimer disease patients and controls. Brain Res 722, 71-77. 
[130] Beffert U, Cohn JS, Petit-Turcotte C, Tremblay M, Aumont N, Ramassamy C, Davignon J, Poirier J 
(1999) Apolipoprotein E and β-amyloid levels in the hippocampus and frontal cortex of Alzheimer's 
disease subjects are disease-related and apolipoprotein E genotype dependent. Brain Res 843, 87-94. 
 54 
[131] Chouinard-Watkins R, Rioux-Perreault C, Fortier M, Tremblay-Mercier J, Zhang Y, Lawrence P, 
Vohl MC, Perron P, Lorrain D, Brenna JT, Cunnane SC, Plourde M (2013) Disturbance in uniformly 
13C-labelled DHA metabolism in elderly human subjects carrying the apoE epsilon4 allele. Br J 
Nutr 110, 1751-1759. 
[132] Smith JD, Miyata M, Poulin SE, Neveux LM, Craig WY (1998) The relationship between 
apolipoprotein E and serum oxidation-related variables is apolipoprotein E phenotype dependent. Int 
J Clin Lab Res 28, 116-121. 
[133] Martin V, Fabelo N, Santpere G, Puig B, Marin R, Ferrer I, Diaz M (2010) Lipid alterations in lipid 
rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis 19, 489-502. 
[134] Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the 
Alzheimer β-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123. 
[135] Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase 
immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 
56, 1065-1073. 
[136] Wang X, Zhu M, Hjorth E, Cortes-Toro V, Eyjolfsdottir H, Graff C, Nennesmo I, Palmblad J, 
Eriksdotter M, Sambamurti K, Fitzgerald JM, Serhan CN, Granholm AC, Schultzberg M (2015) 
Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement 11, 40-50 e42. 
[137] Mohri I, Kadoyama K, Kanekiyo T, Sato Y, Kagitani-Shimono K, Saito Y, Suzuki K, Kudo T, 
Takeda M, Urade Y, Murayama S, Taniike M (2007) Hematopoietic prostaglandin D synthase and 
DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from 
human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 66, 469-480. 
[138] Bate C, Kempster S, Williams A (2006) Prostaglandin D2 mediates neuronal damage by amyloid-β 
or prions which activates microglial cells. Neuropharmacology 50, 229-237. 
[139] Hedqvist P, Raud J, Palmertz U, Haeggstrom J, Nicolaou KC, Dahlen SE (1989) Lipoxin A4 inhibits 
leukotriene B4-induced inflammation in the hamster cheek pouch. Acta Physiol Scand 137, 571-572. 
[140] Chiang N, Takano T, Clish CB, Petasis NA, Tai HH, Serhan CN (1998) Aspirin-triggered 15-epi-
lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of 
a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther 287, 779-790. 
[141] Chiang N, Gronert K, Clish CB, O'Brien JA, Freeman MW, Serhan CN (1999) Leukotriene B4 
receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in 
reperfusion. J Clin Invest 104, 309-316. 
[142] Serhan CN (2006) Novel chemical mediators in the resolution of inflammation: resolvins and 
protectins. Anesthesiol Clin 24, 341-364. 
[143] Serhan CN, Petasis NA (2011) Resolvins and protectins in inflammation resolution. Chem Rev 111, 
5922-5943. 
[144] Miyata J, Fukunaga K, Iwamoto R, Isobe Y, Niimi K, Takamiya R, Takihara T, Tomomatsu K, 
Suzuki Y, Oguma T, Sayama K, Arai H, Betsuyaku T, Arita M, Asano K (2013) Dysregulated 
synthesis of protectin D1 in eosinophils from patients with severe asthma. J Allergy Clin Immunol 
131, 353-360 e351-352. 
[145] Planaguma A, Kazani S, Marigowda G, Haworth O, Mariani TJ, Israel E, Bleecker ER, Curran-
Everett D, Erzurum SC, Calhoun WJ, Castro M, Chung KF, Gaston B, Jarjour NN, Busse WW, 
Wenzel SE, Levy BD (2008) Airway lipoxin A4 generation and lipoxin A4 receptor expression are 
decreased in severe asthma. Am J Respir Crit Care Med 178, 574-582. 
[146] Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE (2011) Impaired 
phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS ONE 6, e24422. 
[147] Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M 
(2008) Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of 
asthma. Biochem Biophys Res Commun 367, 509-515. 
[148] Levy BD, Lukacs NW, Berlin AA, Schmidt B, Guilford WJ, Serhan CN, Parkinson JF (2007) 
Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 
receptor antagonism. FASEB J 21, 3877-3884. 
[149] Flesher RP, Herbert C, Kumar RK (2014) Resolvin E1 promotes resolution of inflammation in a 
mouse model of an acute exacerbation of allergic asthma. Clin Sci 126, 805-814. 
[150] Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, 
Suramanyam B, Guilford WJ, Parkinson JF (2004) A β-oxidation-resistant lipoxin A4 analog treats 
hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S 
A 101, 15736-15741. 
[151] Marcon R, Bento AF, Dutra RC, Bicca MA, Leite DF, Calixto JB (2013) Maresin 1, a proresolving 
lipid mediator derived from omega-3 polyunsaturated Fatty acids, exerts protective actions in murine 
models of colitis. J Immunol 191, 4288-4298. 
[152] Yamada T, Tani Y, Nakanishi H, Taguchi R, Arita M, Arai H (2011) Eosinophils promote resolution 
of acute peritonitis by producing proresolving mediators in mice. FASEB J 25, 561-568. 
[153] Arita M, Ohira T, Sun YP, Elangovan S, Chiang N, Serhan CN (2007) Resolvin E1 selectively 
interacts with leukotriene B4 receptor BLT1 and ChemR23 to regulate inflammation. J Immunol 
178, 3912-3917. 
  55 
[154] Bazan NG, Eady TN, Khoutorova L, Atkins KD, Hong S, Lu Y, Zhang C, Jun B, Obenaus A, 
Fredman G, Zhu M, Winkler JW, Petasis NA, Serhan CN, Belayev L (2012) Novel aspirin-triggered 
neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Exp Neurol 236, 
122-130. 
[155] Sobrado M, Pereira MP, Ballesteros I, Hurtado O, Fernandez-Lopez D, Pradillo JM, Caso JR, 
Vivancos J, Nombela F, Serena J, Lizasoain I, Moro MA (2009) Synthesis of lipoxin A4 by 5-
lipoxygenase mediates PPARγ-dependent, neuroprotective effects of rosiglitazone in experimental 
stroke. J Neurosci 29, 3875-3884. 
[156] Wu Y, Wang YP, Guo P, Ye XH, Wang J, Yuan SY, Yao SL, Shang Y (2012) A lipoxin A4 analog 
ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal 
cerebral ischemia-reperfusion injury. J Mol Neurosci 46, 483-491. 
[157] Ye XH, Wu Y, Guo PP, Wang J, Yuan SY, Shang Y, Yao SL (2010) Lipoxin A4 analogue protects 
brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 
1323, 174-183. 
[158] Wu L, Miao S, Zou LB, Wu P, Hao H, Tang K, Zeng P, Xiong J, Li HH, Wu Q, Cai L, Ye DY 
(2012) Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a 
neuroprotective effect in cerebral ischemia/reperfusion injury. J Mol Neurosci 48, 185-200. 
[159] Huang L, Wang CF, Serhan CN, Strichartz G (2011) Enduring prevention and transient reduction of 
postoperative pain by intrathecal resolvin D1. Pain 152, 557-565. 
[160] Hu S, Mao-Ying QL, Wang J, Wang ZF, Mi WL, Wang XW, Jiang JW, Huang YL, Wu GC, Wang 
YQ (2012) Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with 
suppressing expression of spinal proinflammatory cytokines. J Neuroinflammation 9, 278. 
[161] Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, Ji RR, Zhu M, Petasis NA (2012) 
Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. 
FASEB J 26, 1755-1765. 
[162] Xu ZZ, Liu XJ, Berta T, Park CK, Lu N, Serhan CN, Ji RR (2013) NpD/PD1 protects against 
neuropathic pain in mice after nerve trauma. Ann Neurol 74, 490-495. 
[163] Park CK, Lu N, Xu ZZ, Liu T, Serhan CN, Ji RR (2011) Resolving TRPV1- and TNF-α-mediated 
spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci 31, 15072-
15085. 
[164] Medeiros R, Kitazawa M, Passos GF, Baglietto-Vargas D, Cheng D, Cribbs DH, LaFerla FM (2013) 
Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer 
disease-like pathology in mice. Am J Pathol 182, 1780-1789. 
[165] Dunn HC, Ager RR, Baglietto-Vargas D, Cheng D, Kitazawa M, Cribbs DH, Medeiros R (2015) 
Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD 
mouse model. J Alzheimers Dis 43, 893-903. 
[166] Wu SH, Chen XQ, Liu B, Wu HJ, Dong L (2013) Efficacy and safety of 15(R/S)-methyl-lipoxin 
A(4) in topical treatment of infantile eczema. Br J Dermatol 168, 172-178. 
[167] de Paiva CS, Schwartz CE, Gjorstrup P, Pflugfelder SC (2012) Resolvin E1 (RX-10001) reduces 
corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry 
eye. Cornea 31, 1299-1303. 
[168] Li N, He J, Schwartz CE, Gjorstrup P, Bazan HE (2010) Resolvin E1 improves tear production and 
decreases inflammation in a dry eye mouse model. J Ocul Pharmacol Ther 26, 431-439. 
[169] Maddox JF, Hachicha M, Takano T, Petasis NA, Fokin VV, Serhan CN (1997) Lipoxin A4 stable 
analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked 
lipoxin A4 receptor. J Biol Chem 272, 6972-6978. 
[170] Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, Petasis NA, Serhan CN 
(2010) Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl 
Acad Sci U S A 107, 1660-1665. 
[171] Arita M, Bianchini F, Aliberti J, Sher A, Chiang N, Hong S, Yang R, Petasis NA, Serhan CN (2005) 
Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid 
mediator resolvin E1. J Exp Med 201, 713-722. 
[172] Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy 
PM, Oppenheim JJ, Wang JM (2001) Aβ42 activates a G-protein-coupled chemoattractant receptor, 
FPR-like-1. J Neurosci 21, RC123. 
[173] Bondue B, Wittamer V, Parmentier M (2011) Chemerin and its receptors in leukocyte trafficking, 
inflammation and metabolism. Cytokine Growth Factor Rev 22, 331-338. 
[174] Fulop P, Seres I, Lorincz H, Harangi M, Somodi S, Paragh G (2014) Association of chemerin with 
oxidative stress, inflammation and classical adipokines in non-diabetic obese patients. J Cell Mol 
Med 18, 1313-1320. 
[175] Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG (2011) Docosahexaenoic 
acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARγ-mediated 
mechanisms in Alzheimer's disease models. PLoS ONE 6, e15816. PMID: 21246057. 
[176] Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky 
JM (2010) GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and 
insulin-sensitizing effects. Cell 142, 687-698. 
 56 
[177] Radmark O, Werz O, Steinhilber D, Samuelsson B (2015) 5-Lipoxygenase, a key enzyme for 
leukotriene biosynthesis in health and disease. Biochim Biophys Acta 1851, 331-339. 
[178] Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ (2006) 
Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. 
Neuropathology 26, 99-106. 
[179] Firuzi O, Zhuo J, Chinnici CM, Wisniewski T, Pratico D (2008) 5-Lipoxygenase gene disruption 
reduces Aβ pathology in a mouse model of Alzheimer's disease. FASEB J 22, 1169-1178. 
[180] Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC (2012) Minocycline corrects early, 
pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-
like amyloid pathology. J Neuroinflammation 9, 62. 
[181] Radmark O, Werz O, Steinhilber D, Samuelsson B (2007) 5-Lipoxygenase: regulation of expression 
and enzyme activity. Trends Biochem Sci 32, 332-341. 
[182] Ye Y, Lin Y, Perez-Polo JR, Uretsky BF, Ye Z, Tieu BC, Birnbaum Y (2008) Phosphorylation of 5-
lipoxygenase at ser523 by protein kinase A determines whether pioglitazone and atorvastatin induce 
proinflammatory leukotriene B4 or anti-inflammatory 15-epi-lipoxin A4 production. J Immunol 181, 
3515-3523. 
[183] Luo M, Jones SM, Phare SM, Coffey MJ, Peters-Golden M, Brock TG (2004) Protein kinase A 
inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 279, 
41512-41520. 
[184] Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D (2005) Elevation of 12/15 lipoxygenase 
products in AD and mild cognitive impairment. Ann Neurol 58, 623-626. 
[185] Berger M, Schwarz K, Thiele H, Reimann I, Huth A, Borngraber S, Kuhn H, Thiele BJ (1998) 
Simultaneous expression of leukocyte-type 12-lipoxygenase and reticulocyte-type 15-lipoxygenase 
in rabbits. J Mol Biol 278, 935-948. 
[186] Joshi YB, Giannopoulos PF, Pratico D (2015) The 12/15-lipoxygenase as an emerging therapeutic 
target for Alzheimer's disease. Trends Pharmacol Sci 36, 181-186. 
[187] Pratico D, Zhukareva V, Yao Y, Uryu K, Funk CD, Lawson JA, Trojanowski JQ, Lee VM (2004) 
12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative 
stress. Am J Pathol 164, 1655-1662. 
[188] Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, Shappell SB, Yang P, Newman 
RA, Tang DG (2003) Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 
(15-LOX2) and its splice variants. J Biol Chem 278, 25091-25100. 
[189] Moussalli MJ, Wu Y, Zuo X, Yang XL, Wistuba, II, Raso MG, Morris JS, Bowser JL, Minna JD, 
Lotan R, Shureiqi I (2011) Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss 
in cancer cells to terminal cell differentiation evasion. Cancer Prev Res (Phila) 4, 1961-1972. 
[190] Wu Y, Fang B, Yang XQ, Wang L, Chen D, Krasnykh V, Carter BZ, Morris JS, Shureiqi I (2008) 
Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer. Mol Ther 16, 886-892. 
[191] Zhu H, Glasgow W, George MD, Chrysovergis K, Olden K, Roberts JD, Eling T (2008) 15-
lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. Int J Cancer 123, 
2741-2749. 
[192] Hsi LC, Wilson LC, Eling TE (2002) Opposing effects of 15-lipoxygenase-1 and -2 metabolites on 
MAPK signaling in prostate. Alteration in peroxisome proliferator-activated receptor gamma. J Biol 
Chem 277, 40549-40556. 
[193] Ivanov I, Heydeck D, Hofheinz K, Roffeis J, O'Donnell VB, Kuhn H, Walther M (2010) Molecular 
enzymology of lipoxygenases. Arch Biochem Biophys 503, 161-174. 
[194] Chen B, Tsui S, Boeglin WE, Douglas RS, Brash AR, Smith TJ (2006) Interleukin-4 induces 15-
lipoxygenase-1 expression in human orbital fibroblasts from patients with Graves disease. Evidence 
for anatomic site-selective actions of Th2 cytokines. J Biol Chem 281, 18296-18306. 
[195] Succol F, Pratico D (2007) A role for 12/15 lipoxygenase in the amyloid-β precursor protein 
metabolism. J Neurochem 103, 380-387. 
[196] Yang H, Zhuo JM, Chu J, Chinnici C, Pratico D (2010) Amelioration of the Alzheimer's disease 
phenotype by absence of 12/15-lipoxygenase. Biol Psychiatry 68, 922-929. 
[197] Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P (2001) 
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta 
Neuropathol 101, 2-8. 
[198] Yermakova AV, O'Banion MK (2001) Downregulation of neuronal cyclooxygenase-2 expression in 
end stage Alzheimer's disease. Neurobiol Aging 22, 823-836. 
[199] Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008) 
Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 
14, 1419-1427. 
[200] Botting RM (2006) Inhibitors of cyclooxygenases: mechanisms, selectivity and uses. J Physiol 
Pharmacol 57 Suppl 5, 113-124. 
[201] Claria J, Serhan CN (1995) Aspirin triggers previously undescribed bioactive eicosanoids by human 
endothelial cell-leukocyte interactions. Proc Natl Acad Sci U S A 92, 9475-9479. 
  57 
[202] Serhan CN (2005) Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of 
endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73, 141-
162. 
[203] Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav 
Brain Res 221, 555-563. 
[204] Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease 
and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239. 
[205] Bowen DM, Smith CB, White P, Davison AN (1976) Neurotransmitter-related enzymes and indices 
of hypoxia in senile dementia and other abiotrophies. Brain 99, 459-496. 
[206] Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. 
Lancet 2, 1403. 
[207] Oz M, Lorke DE, Yang KH, Petroianu G (2013) On the interaction of β-amyloid peptides and α7-
nicotinic acetylcholine receptors in Alzheimer's disease. Curr Alzheimer Res 10, 618-630. 
[208] Perumal D, Pillai S, Nguyen J, Schaal C, Coppola D, Chellappan SP (2014) Nicotinic acetylcholine 
receptors induce c-Kit ligand/Stem Cell Factor and promote stemness in an ARRB1/ β-arrestin-1 
dependent manner in NSCLC. Oncotarget 5, 10486-10502. 
[209] Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, 
Tan J (2004) Cholinergic modulation of microglial activation by α7 nicotinic receptors. J Neurochem 
89, 337-343. 
[210] Yang J, Shi SQ, Shi L, Fang D, Liu H, Garfield RE (2014) Nicotine, an α7 nAChR agonist, reduces 
lipopolysaccharide-induced inflammatory responses and protects fetuses in pregnant rats. Am J 
Obstet Gynecol 211, 538 e531-537. 
[211] Moon JH, Kim SY, Lee HG, Kim SU, Lee YB (2008) Activation of nicotinic acetylcholine receptor 
prevents the production of reactive oxygen species in fibrillar Aβ42-stimulated microglia. Exp Mol 
Med 40, 11-18. 
[212] Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during 
acute inflammation: signals in resolution. Nat Immunol 2, 612-619. 
[213] Janabi N, Peudenier S, Heron B, Ng KH, Tardieu M (1995) Establishment of human microglial cell 
lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T 
antigen. Neurosci Lett 195, 105-108. 
[214] Biedler JL, Helson L, Spengler BA (1973) Morphology and growth, tumorigenicity, and cytogenetics 
of human neuroblastoma cells in continuous culture. Cancer Res 33, 2643-2652. 
[215] Xie HR, Hu LS, Li GY (2010) SH-SY5Y human neuroblastoma cell line: in vitro cell model of 
dopaminergic neurons in Parkinson's disease. Chin Med J (Engl) 123, 1086-1092. 
[216] Agholme L, Lindstrom T, Kagedal K, Marcusson J, Hallbeck M (2010) An in vitro model for 
neuroscience: differentiation of SH-SY5Y cells into cells with morphological and biochemical 
characteristics of mature neurons. J Alzheimers Dis 20, 1069-1082. 
[217] Norden B, Broberg P, Lindberg C, Plymoth A (2005) Analysis and understanding of high-
dimensionality data by means of multivariate data analysis. Chem Biodivers 2, 1487-1494. 
[218] Xia W, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ (2009) A specific enzyme-
linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain 
tissue of patients with Alzheimer disease. Arch Neurol 66, 190-199. 
[219] Steinerman JR, Irizarry M, Scarmeas N, Raju S, Brandt J, Albert M, Blacker D, Hyman B, Stern Y 
(2008) Distinct pools of β-amyloid in Alzheimer disease-affected brain: a clinicopathologic study. 
Arch Neurol 65, 906-912. 
[220] Morris JC (2005) Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 19, 
163-165. 
[221] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., 
Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, 
Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical 
stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 
280-292. 
[222] Mansson C, Arosio P, Hussein R, Kampinga HH, Hashem RM, Boelens WC, Dobson CM, Knowles 
TP, Linse S, Emanuelsson C (2014) Interaction of the molecular chaperone DNAJB6 with growing 
Aβ42 aggregates leads to sub-stoichiometric inhibition of amyloid formation. J Biol Chem 289, 
31066-31076. 
[223] Lindberg C, Selenica ML, Westlind-Danielsson A, Schultzberg M (2005) β-amyloid protein structure 
determines the nature of cytokine release from rat microglia. J Mol Neurosci 27, 1-12. 
[224] Dalli J, Zhu M, Vlasenko NA, Deng B, Haeggstrom JZ, Petasis NA, Serhan CN (2013) The novel 
13S,14S-epoxy-maresin is converted by human macrophages to maresin 1 (MaR1), inhibits 
leukotriene A4 hydrolase (LTA4H), and shifts macrophage phenotype. FASEB J 27, 2573-2583. 
[225] Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, Oh SF, Spite M (2009) Maresins: 
novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 206, 
15-23. 
 58 
[226] Mizwicki MT, Liu G, Fiala M, Magpantay L, Sayre J, Siani A, Mahanian M, Weitzman R, Hayden 
EY, Rosenthal MJ, Nemere I, Ringman J, Teplow DB (2013) 1α,25-dihydroxyvitamin D3 and 
resolvin D1 retune the balance between amyloid-β phagocytosis and inflammation in Alzheimer's 
disease patients. J Alzheimers Dis 34, 155-170. 
[227] Ariel A, Serhan CN (2012) New lives given by cell death: macrophage differentiation following their 
encounter with apoptotic leukocytes during the resolution of inflammation. Front Immunol 3, 4. 
[228] El Kebir D, Gjorstrup P, Filep JG (2012) Resolvin E1 promotes phagocytosis-induced neutrophil 
apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci U S A 109, 
14983-14988. 
[229] Noda M, Suzumura A (2012) Sweepers in the CNS: Microglial Migration and Phagocytosis in the 
Alzheimer Disease Pathogenesis. Int J Alzheimers Dis 2012, 891087. 
[230] Koenigsknecht-Talboo J, Landreth GE (2005) Microglial phagocytosis induced by fibrillar β-
amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci 25, 8240-
8249. 
[231] Obulesu M, Jhansilakshmi M (2014) Neuroinflammation in Alzheimer's disease: an understanding of 
physiology and pathology. Int J Neurosci 124, 227-235. 
[232] Latta CH, Brothers HM, Wilcock DM (2014) Neuroinflammation in Alzheimer's disease; A source 
of heterogeneity and target for personalized therapy. Neuroscience. 
[233] Hjorth E, Frenkel D, Weiner H, Schultzberg M (2010) Effects of immunomodulatory substances on 
phagocytosis of Aβ42 by human microglia. Int J Alzheimers Dis 2010. 
[234] Majumdar A, Cruz D, Asamoah N, Buxbaum A, Sohar I, Lobel P, Maxfield FR (2007) Activation of 
microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. Mol Biol Cell 
18, 1490-1496. 
[235] Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, Groyer G, Adams D, 
Schumacher M (2010) Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological 
and psychiatric disorders. Nat Rev Drug Discov 9, 971-988. 
[236] Fuentes-Duculan J, Suarez-Farinas M, Zaba LC, Nograles KE, Pierson KC, Mitsui H, Pensabene 
CA, Kzhyshkowska J, Krueger JG, Lowes MA (2010) A subpopulation of CD163-positive 
macrophages is classically activated in psoriasis. J Invest Dermatol 130, 2412-2422. 
[237] Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, 
Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through 
GPR120. Nat Med 11, 90-94. 
[238] Heneka MT, Reyes-Irisarri E, Hull M, Kummer MP (2011) Impact and Therapeutic Potential of 
PPARs in Alzheimer's Disease. Curr Neuropharmacol 9, 643-650. 
[239] Liao Z, Dong J, Wu W, Yang T, Wang T, Guo L, Chen L, Xu D, Wen F (2012) Resolvin D1 
attenuates inflammation in lipopolysaccharide-induced acute lung injury through a process involving 
the PPARγ/NF-κB pathway. Respir Res 13, 110. 
[240] Hajjar T, Meng GY, Rajion MA, Vidyadaran S, Othman F, Farjam AS, Li TA, Ebrahimi M (2012) 
Omega 3 polyunsaturated fatty acid improves spatial learning and hippocampal peroxisome 
proliferator activated receptors (PPARα and PPARγ) gene expression in rats. BMC Neurosci 13, 109. 
[241] Kummer MP, Heneka MT (2008) PPARs in Alzheimer's Disease. PPAR Res 2008, 403896. 
[242] Filiou MD, Arefin AS, Moscato P, Graeber MB (2014) 'Neuroinflammation' differs categorically 
from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and 
inflammatory diseases compared. Neurogenetics 15, 201-212. 
[243] Perry VH, Matyszak MK, Fearn S (1993) Altered antigen expression of microglia in the aged rodent 
CNS. Glia 7, 60-67. 
[244] Sheffield LG, Berman NE (1998) Microglial expression of MHC class II increases in normal aging 
of nonhuman primates. Neurobiol Aging 19, 47-55. 
[245] Wei J, Xu H, Davies JL, Hemmings GP (1992) Increase of plasma IL-6 concentration with age in 
healthy subjects. Life Sci 51, 1953-1956. 
[246] de Gonzalo-Calvo D, Neitzert K, Fernandez M, Vega-Naredo I, Caballero B, Garcia-Macia M, 
Suarez FM, Rodriguez-Colunga MJ, Solano JJ, Coto-Montes A (2010) Differential inflammatory 
responses in aging and disease: TNF-α and IL-6 as possible biomarkers. Free Radic Biol Med 49, 
733-737. 
[247] Wang X, Puerta E, Cedazo-Minguez A, Hjorth E, Schultzberg M (2015) Insufficient resolution 
response in the hippocampus of a senescence-accelerated mouse model--SAMP8. J Mol Neurosci 55, 
396-405. 
[248] Solito E, Sastre M (2012) Microglia function in Alzheimer's disease. Front Pharmacol 3, 14. 
[249] Heneka MT, Sastre M, Dumitrescu-Ozimek L, Dewachter I, Walter J, Klockgether T, Van Leuven F 
(2005) Focal glial activation coincides with increased BACE1 activation and precedes amyloid 
plaque deposition in APP[V717I] transgenic mice. J Neuroinflammation 2, 22. 
[250] Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA (2010) 
Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. 
Neurodegener Dis 7, 38-41. 
[251] Beard CM, Kokman E, Kurland LT (1991) Rheumatoid arthritis and susceptibility to Alzheimer's 
disease. Lancet 337, 1426. 
  59 
[252] Cunnane SC, Plourde M, Pifferi F, Begin M, Feart C, Barberger-Gateau P (2009) Fish, 
docosahexaenoic acid and Alzheimer's disease. Prog Lipid Res 48, 239-256. 
[253] Imbimbo BP, Solfrizzi V, Panza F (2010) Are NSAIDs useful to treat Alzheimer's disease or mild 
cognitive impairment? Front Aging Neurosci 2. 
[254] Rogers PJ, Appleton KM, Kessler D, Peters TJ, Gunnell D, Hayward RC, Heatherley SV, Christian 
LM, McNaughton SA, Ness AR (2008) No effect of n-3 long-chain polyunsaturated fatty acid (EPA 
and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. 
Br J Nutr 99, 421-431. 
[255] Chiu CC, Su KP, Cheng TC, Liu HC, Chang CJ, Dewey ME, Stewart R, Huang SY (2008) The 
effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a 
preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol 
Psychiatry 32, 1538-1544. 
[256] Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin 
I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild 
to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 
1402-1408. 
[257] Daiello LA, Gongvatana A, Dunsiger S, Cohen RA, Ott BR, Alzheimer's Disease Neuroimaging I 
(2015) Association of fish oil supplement use with preservation of brain volume and cognitive 
function. Alzheimers Dement 11, 226-235. 
[258] Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM (1997) Dietary fat intake and 
the risk of incident dementia in the Rotterdam Study. Ann Neurol 42, 776-782. 
[259] Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, Witteman JC, Breteler MM 
(2002) Diet and risk of dementia: Does fat matter?: The Rotterdam Study. Neurology 59, 1915-1921. 
[260] Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S (2002) Fish, 
meat, and risk of dementia: cohort study. BMJ 325, 932-933. 
[261] Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, Basun H, Faxen-Irving G, Garlind A, Vedin 
I, Vessby B, Wahlund LO, Palmblad J (2006) Omega-3 fatty acid treatment in 174 patients with mild 
to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 63, 
1402-1408. 
[262] Bright JM, Sullivan PS, Melton SL, Schneider JF, McDonald TP (1994) The effects of n-3 fatty acid 
supplementation on bleeding time, plasma fatty acid composition, and in vitro platelet aggregation in 
cats. J Vet Intern Med 8, 247-252. 
[263] Kelley DS, Taylor PC, Nelson GJ, Mackey BE (1998) Dietary docosahexaenoic acid and 
immunocompetence in young healthy men. Lipids 33, 559-566. 
[264] Cooper AL, Gibbons L, Horan MA, Little RA, Rothwell NJ (1993) Effect of dietary fish oil 
supplementation on fever and cytokine production in human volunteers. Clin Nutr 12, 321-328. 
[265] Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J, 3rd, Spur BW, Robinson DR, Corey EJ, 
Lewis RA, Austen KF (1985) Effect of dietary enrichment with eicosapentaenoic and 
docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil 
function. N Engl J Med 312, 1217-1224. 
[266] Traversa G, Walker AM, Ippolito FM, Caffari B, Capurso L, Dezi A, Koch M, Maggini M, Alegiani 
SS, Raschetti R (1995) Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. 
Epidemiology 6, 49-54. 
[267] Balfour JA, Plosker GL (1999) Rosiglitazone. Drugs 57, 921-930; discussion 931-922. 
[268] Montaner LJ, da Silva RP, Sun J, Sutterwala S, Hollinshead M, Vaux D, Gordon S (1999) Type 1 
and type 2 cytokine regulation of macrophage endocytosis: differential activation by IL-4/IL-13 as 
opposed to IFN-γ or IL-10. J Immunol 162, 4606-4613. 
[269] Huang TL, Zandi PP, Tucker KL, Fitzpatrick AL, Kuller LH, Fried LP, Burke GL, Carlson MC 
(2005) Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. 
Neurology 65, 1409-1414. 
[270] Whalley LJ, Deary IJ, Starr JM, Wahle KW, Rance KA, Bourne VJ, Fox HC (2008) n-3 Fatty acid 
erythrocyte membrane content, APOE varepsilon4, and cognitive variation: an observational follow-
up study in late adulthood. Am J Clin Nutr 87, 449-454. 
[271] Martin BK, Meinert CL, Breitner JC, Group AR (2002) Double placebo design in a prevention trial 
for Alzheimer's disease. Control Clin Trials 23, 93-99. 
[272] Beyer I, Njemini R, Bautmans I, Demanet C, Mets T (2012) Immunomodulatory effect of NSAID in 
geriatric patients with acute infection: effects of piroxicam on chemokine/cytokine secretion patterns 
and levels of heat shock proteins. A double-blind randomized controlled trial. (ISRCTN58517443). 
Cell Stress Chaperones 17, 255-265. 
 
